| Year |
Citation |
Score |
| 2023 |
Venneti S, Kawakibi AR, Ji S, Waszak SM, Sweha SR, Mota M, Pun M, Deogharkar A, Chung C, Tarapore RS, Ramage S, Chi A, Wen PY, Arrillaga-Romany I, Batchelor TT, ... ... Cloughesy TF, et al. Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways. Cancer Discovery. PMID 37584601 DOI: 10.1158/2159-8290.CD-23-0131 |
0.34 |
|
| 2023 |
Nassiri F, Patil V, Yefet LS, Singh O, Liu J, Dang RMA, Yamaguchi TN, Daras M, Cloughesy TF, Colman H, Kumthekar PU, Chen CC, Aiken R, Groves MD, Ong SS, et al. Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial. Nature Medicine. PMID 37188783 DOI: 10.1038/s41591-023-02347-y |
0.312 |
|
| 2022 |
Omuro A, Brandes AA, Carpentier AF, Idbaih A, Reardon DA, Cloughesy T, Sumrall A, Baehring J, van den Bent M, Bähr O, Lombardi G, Mulholland P, Tabatabai G, Lassen U, Sepulveda JM, et al. Radiotherapy Combined With Nivolumab or Temozolomide for Newly Diagnosed Glioblastoma With Unmethylated MGMT Promoter: An International Randomized Phase 3 Trial. Neuro-Oncology. PMID 35419607 DOI: 10.1093/neuonc/noac099 |
0.315 |
|
| 2021 |
He L, Bhat K, Ioannidis A, Zhang L, Nguyen NT, Allen JE, Nghiemphu PL, Cloughesy TF, Liau LM, Kornblum HI, Pajonk F. Effects of the DRD2/3 Antagonist ONC201 and Radiation in Glioblastoma. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. PMID 34097975 DOI: 10.1016/j.radonc.2021.05.027 |
0.301 |
|
| 2020 |
Cloughesy TF, Petrecca K, Walbert T, Butowski N, Salacz M, Perry J, Damek D, Bota D, Bettegowda C, Zhu JJ, Iwamoto F, Placantonakis D, Kim L, Elder B, Kaptain G, et al. Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial. Jama Oncology. PMID 33119048 DOI: 10.1001/jamaoncol.2020.3161 |
0.341 |
|
| 2020 |
Reardon DA, Desjardins A, Rixe O, Cloughesy T, Alekar S, Williams JH, Li R, Taylor CT, Lassman AB. A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma. Investigational New Drugs. PMID 32436060 DOI: 10.1007/s10637-020-00950-1 |
0.37 |
|
| 2020 |
Peters KB, Cohen AL, Butowski NA, Villano JL, Giglio P, McGranahan T, Zhang C, Cloughesy TF, Herndon JE, Healy P, MacLeod D, Penchev S, Silberstein D, Batinic-Haberle I, Spasojevic I, et al. BMX-HGG: Phase II trial of newly diagnosed high-grade glioma treated with concurrent radiation therapy, temozolomide, and BMX-001. Journal of Clinical Oncology. 38: TPS2577-TPS2577. DOI: 10.1200/Jco.2020.38.15_Suppl.Tps2577 |
0.317 |
|
| 2020 |
Mellinghoff IK, Van Den Bent MJ, Clarke JL, Maher EA, Peters KB, Touat M, De Groot JF, De La Fuente MI, Arrillaga-Romany I, Wick W, Ellingson BM, Schoenfeld S, Tai F, Le K, Lu M, ... ... Cloughesy TF, et al. INDIGO: A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881) vs placebo in patients (pts) with residual or recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation. Journal of Clinical Oncology. 38: TPS2574-TPS2574. DOI: 10.1200/jco.2020.38.15_suppl.tps2574 |
0.308 |
|
| 2020 |
Arrillaga-Romany I, Kurz SC, Tarapore R, Sumrall A, Butowski NA, Harrison RA, De Groot JF, Chi AS, Shonka NA, Umemura Y, Odia Y, Mehta MP, Nghiemphu PL, Cloughesy TF, Lu G, et al. Single-agent ONC201 in recurrent H3 K27M-mutant diffuse midline glioma. Journal of Clinical Oncology. 38: 3615-3615. DOI: 10.1200/Jco.2020.38.15_Suppl.3615 |
0.323 |
|
| 2020 |
Molaie D, Lai A, Ellingson BM, Nguyen T, Bahng HH, Filka E, Green S, Pope WB, Leng M, Yong WH, Green RM, Polikoff J, Spier L, Iwamoto FM, Lassman AB, ... Cloughesy TF, et al. Phase II trial of bevacizumab and temozolomide for treatment of elderly patients with newly diagnosed glioblastoma. Journal of Clinical Oncology. 38: 2540-2540. DOI: 10.1200/Jco.2020.38.15_Suppl.2540 |
0.342 |
|
| 2020 |
Ellingson BM, Huang RY, Villanueva-Meyer J, Lim-Fat MJ, George E, Iorgulescu B, Young G, Raymond C, Oughourlian T, Schlossman J, Gleason T, Oberheim Bush NA, Wen PY, Cloughesy TF, Chang SM, et al. Estimated clinical efficacy and radiographic response characteristics of PD1 inhibition in newly diagnosed and recurrent glioblastoma in clinical practice: A report from the iRANO Working Group. Journal of Clinical Oncology. 38: 2521-2521. DOI: 10.1200/Jco.2020.38.15_Suppl.2521 |
0.32 |
|
| 2020 |
Antonios JP, Everson RG, Mochizuki A, Khattab S, Soto H, Romiyo P, Sun MZ, Moughon D, Billingslea-Yoon E, Odesa S, Li G, Kawaguchi E, Salazar A, Yong W, Schlossman J, ... ... Cloughesy T, et al. Abstract PR13: Adjuvant TLR-3 administration enhances proinflammatory immune responses and is associated with extended survival in glioblastoma patients treated with dendritic cell vaccination Cancer Immunology Research. 8. DOI: 10.1158/2326-6074.Tumimm19-Pr13 |
0.374 |
|
| 2020 |
Wen PY, Groot Jd, Battiste JD, Goldlust SA, Garner JS, Simpson JA, Kijlstra J, Olivero A, Cloughesy T. Abstract CT205: Phase 2 study to evaluate the safety, pharmacokinetics, and clinical activity of the PI3K / mTOR inhibitor paxalisib (GDC-0084) in glioblastoma (GBM) with unmethylated O6-methylguanine-methyltransferase (MGMT) promotor status Cancer Research. 80. DOI: 10.1158/1538-7445.Am2020-Ct205 |
0.397 |
|
| 2020 |
Richardson A, Collins S, Inagaki A, Armstrong V, Robbins D, Ayad N, Gruber H, Jolly D, Cloughesy T, Kasahara N. THER-06. THERAPEUTIC EFFICACY OF RRV-MEDIATED PRODRUG ACTIVATOR GENE THERAPY IN CLINICAL TRIALS OF RECURRENT HIGH-GRADE GLIOMA AND IN MURINE ORTHOTOPIC MODELS OF INTRACEREBRAL GLIOMA AND INTRACEREBELLAR MEDULLOBLASTOMA Neuro-Oncology. 22: iii472-iii472. DOI: 10.1093/neuonc/noaa222.856 |
0.313 |
|
| 2020 |
Mellinghoff I, van den Bent M, Clarke J, Maher E, Peters K, Touat M, de Groot J, De La Fuente M, Arrillaga-Romany I, Wick W, Ellingson B, Schoenfeld S, Liu H, Le K, Lu M, ... ... Cloughesy T, et al. RTID-05. INDIGO: A GLOBAL, RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF VORASIDENIB (AG-881) VS PLACEBO IN PATIENTS WITH RESIDUAL/RECURRENT GRADE II GLIOMA WITH AN ISOCITRATE DEHYDROGENASE 1/2 (IDH1/2) MUTATION Neuro-Oncology. 22: ii194-ii194. DOI: 10.1093/neuonc/noaa215.810 |
0.354 |
|
| 2020 |
Ellingson B, Cloughesy T, Wang C, Patel K, Raymond C, Brenner A, de Groot J, Butowski N, Zach L, Campian J, Schlossman J, Rizvi S, Cohen Y, Lowenton-Spier N, Minei TR, et al. NIMG-17. VALIDATION OF DIFFUSION MRI AS AN IMAGING BIOMARKER FOR BEVACIZUMAB THERAPY IN RECURRENT GLIOBLASTOMA IN A RANDOMIZED PHASE III TRIAL OF BEVACIZUMAB WITH OR WITHOUT VB-111 (GLOBE) Neuro-Oncology. 22: ii150-ii150. DOI: 10.1093/neuonc/noaa215.630 |
0.34 |
|
| 2020 |
Arrillaga-Romany I, Kurz S, Tarapore RS, Sumrall A, Butowski N, Harrison R, de Groot J, Chi A, Shonka N, Umemura Y, Odia Y, Mehta M, Nghiemphu P, Cloughesy T, Taylor L, et al. CTNI-37. EFFICACY OF ONC201 IN PATIENTS WITH ONC201 FOR RECURRENT H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA Neuro-Oncology. 22: ii50-ii51. DOI: 10.1093/neuonc/noaa215.204 |
0.306 |
|
| 2020 |
Rahman Kawakibi A, Tarapore RS, Gardner S, Thomas C, Cartaxo R, Yadav VN, Chi A, Kurz S, Wen P, Arrillaga-Romany I, Batchelor T, Butowski N, Sumrall A, Shonka N, Harrison R, ... ... Cloughesy T, et al. CTNI-17. CLINICAL EFFICACY AND PREDICTIVE BIOMARKERS OF ONC201 IN H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA Neuro-Oncology. 22: ii45-ii46. DOI: 10.1093/neuonc/noaa215.184 |
0.32 |
|
| 2019 |
Nguyen HT, Nguyen N, Liu LY, Dovek L, Lenchner D, Harris R, Ozer B, Ravelo A, Sommer N, Sim MS, Elashoff R, Green R, Nghiemphu PL, Cloughesy TF, Ellingson B, et al. Bevacizumab at first recurrence after standard radio-chemotherapy is associated with improved overall survival in glioblastoma patients with large tumor burden. Neuro-Oncology Practice. 6: 103-111. PMID 31386050 DOI: 10.1093/Nop/Npy021 |
0.302 |
|
| 2019 |
Horbinski C, Ligon KL, Brastianos P, Huse JT, Venere M, Chang S, Buckner J, Cloughesy T, Jenkins RB, Giannini C, Nabors LB, Wen PY, Aldape KJ, Lukas RV, Galanis E, et al. The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. Neuro-Oncology. PMID 31276167 DOI: 10.1093/Neuonc/Noz119 |
0.356 |
|
| 2019 |
Rosenthal M, Curry R, Reardon DA, Rasmussen E, Upreti VV, Damore MA, Henary HA, Hill JS, Cloughesy T. Safety, tolerability, and pharmacokinetics of anti-EGFRvIII antibody-drug conjugate AMG 595 in patients with recurrent malignant glioma expressing EGFRvIII. Cancer Chemotherapy and Pharmacology. PMID 31154523 DOI: 10.1007/s00280-019-03879-2 |
0.328 |
|
| 2019 |
Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, Wang AC, Ellingson BM, Rytlewski JA, Sanders CM, Kawaguchi ES, Du L, Li G, Yong WH, Gaffey SC, et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nature Medicine. PMID 30742122 DOI: 10.1038/S41591-018-0337-7 |
0.302 |
|
| 2019 |
Arrillaga I, Kurz S, Sumrall A, Butowski NA, Harrison RA, De Groot JF, Shonka NA, Lieberman FS, Odia Y, Tarapore R, Merdinger K, Allen JE, Oster W, Mehta MP, Cloughesy TF, et al. Single agent ONC201 in adult recurrent H3 K27M-mutant glioma. Journal of Clinical Oncology. 37: 3005-3005. DOI: 10.1200/Jco.2019.37.15_Suppl.3005 |
0.337 |
|
| 2019 |
Reardon DA, Kaley TJ, Dietrich J, Clarke JL, Dunn G, Lim M, Cloughesy TF, Gan HK, Park AJ, Schwarzenberger P, Ricciardi T, Macri MJ, Ryan A, Venhaus RR. Phase II study to evaluate safety and efficacy of MEDI4736 (durvalumab) + radiotherapy in patients with newly diagnosed unmethylated MGMT glioblastoma (new unmeth GBM). Journal of Clinical Oncology. 37: 2032-2032. DOI: 10.1200/Jco.2019.37.15_Suppl.2032 |
0.334 |
|
| 2019 |
Ellingson BM, Raymond C, Yao J, Chakhoyan A, Turley D, Tsung J, Goldman J, Schlossman J, Tan C, Brenner AJ, Butowski NA, Wen PY, Rachmilewitz Minei T, Cohen YC, Harats D, ... Cloughesy TF, et al. Quantitative radiographic analysis of phase II and III trials in recurrent glioblastoma treated with VB-111 with or without bevacizumab or bevacizumab monotherapy. Journal of Clinical Oncology. 37: 2018-2018. DOI: 10.1200/JCO.2019.37.15_SUPPL.2018 |
0.353 |
|
| 2019 |
Cloughesy T, Petrecca K, Walbert T, Butowski N, Salacz M, Perry J, Damek D, Bota D, Bettegowda C, Zhu J, Iwamoto F, Placantonakis D, Martinez N, Elder JB, Kaptain G, et al. LTBK-08. TOCA 511 & TOCA FC VERSUS STANDARD OF CARE IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA Neuro-Oncology. 21: vi284-vi284. DOI: 10.1093/Neuonc/Noz219.1199 |
0.427 |
|
| 2019 |
Rosenthal MA, Balana C, van Linde ME, Sayehli C, Fiedler WM, Wermke M, Massard C, Mellinghoff IK, Khasraw M, Ang A, Rasmussen E, Kast J, Stienen S, Cloughesy TF. ATIM-49 (LTBK-01). AMG 596, A NOVEL ANTI-EGFRVIII BISPECIFIC T CELL ENGAGER (BITE®) MOLECULE FOR THE TREATMENT OF GLIOBLASTOMA (GBM): PLANNED INTERIM ANALYSIS IN RECURRENT GBM (RGBM) Neuro-Oncology. 21: vi283-vi283. DOI: 10.1093/neuonc/noz219.1195 |
0.307 |
|
| 2019 |
Ahluwalia M, Pugh S, Ellingson B, Kotecha R, Cloughesy T, Vogelbaum M, Aldape K, Cui Y, Armstrong T, Mehta M. RBTT-11. NRG ONCOLOGY NRG-BN006: A PHASE II/III RANDOMIZED, OPEN-LABEL STUDY OF TOCA 511 AND TOCA FC WITH STANDARD OF CARE COMPARED TO STANDARD OF CARE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA Neuro-Oncology. 21: vi220-vi221. DOI: 10.1093/Neuonc/Noz175.922 |
0.452 |
|
| 2019 |
Rahman Kawakibi A, Gardner S, Chi A, Kurz S, Wen P, Arrillaga-Romany I, Batchelor T, Butowski N, Sumrall A, Shonka N, Harrison R, DeGroot J, Mehta M, Odia Y, Hall M, ... ... Cloughesy T, et al. PDCT-12. CLINICAL EFFICACY OF ONC201 IN THALAMIC H3 K27M-MUTANT GLIOMA Neuro-Oncology. 21: vi186-vi186. DOI: 10.1093/Neuonc/Noz175.773 |
0.428 |
|
| 2019 |
Yao J, Nathanson D, Yong WH, Salamon N, Lai A, Leia Nghiemphu P, Prins R, Pope W, Czernin J, Everson R, Liau L, Cloughesy T, Ellingson B. NIMG-60. IDH MUTANT GLIOMAS WITH 1p/19q CO-DELETION ARE LESS ACIDIC THAN NON-CO-DELETED GLIOMAS AS MEASURED WITH PH-WEIGHTED AMINE CEST-MRI AND AMINO ACID PET Neuro-Oncology. 21: vi174-vi175. DOI: 10.1093/Neuonc/Noz175.729 |
0.328 |
|
| 2019 |
Patel K, Raymond C, Yao J, Tsung J, Goldman J, Schlossman J, Tran C, Brenner A, Butowski N, Wen P, Pope W, Ji M, Lai A, Leia Nghiemphu P, Rachmilewitz Minei T, ... ... Cloughesy T, et al. NIMG-54. DIFFUSION MRI PHENOTYPES PREDICT OVERALL SURVIVAL BENEFIT FROM BEVACIZUMAB IN RECURRENT GLIOBLASTOMA WITH A LARGE TUMOR BURDEN: EVIDENCE FROM CLINICAL PRACTICE AND A MULTICENTER PHASE 3 TRIAL Neuro-Oncology. 21: vi173-vi173. DOI: 10.1093/Neuonc/Noz175.723 |
0.454 |
|
| 2019 |
Ellingson B, Raymond C, Yao J, Goldman J, Schlossman J, Tran C, Brenner A, Butowski N, Wen P, Rachmilewitz Minei T, Cohen Y, Harats D, Cloughesy T. NIMG-47. VOLUMETRIC ANALYSIS OF PHASE 2 AND 3 TRIALS IN RECURRENT GLIOBLASTOMA TREATED WITH VB-111 WITH OR WITHOUT BEVACIZUMAB OR BEVACIZUMAB MONOTHERAPY Neuro-Oncology. 21: vi172-vi172. DOI: 10.1093/neuonc/noz175.717 |
0.432 |
|
| 2019 |
Ellingson B, Yao J, Raymond C, Nathanson D, Simpson J, Garner J, Olivero A, Mueller L, Rodon J, Gerstner E, Cloughesy T, Wen P. NIMG-34. MULTI-PARAMETRIC MR-PET IMAGING PREDICTS PHARMACOKINETICS AND CLINICAL RESPONSE TO GDC-0084 IN HUMAN RECURRENT HIGH-GRADE GLIOMA Neuro-Oncology. 21: vi168-vi168. DOI: 10.1093/neuonc/noz175.704 |
0.387 |
|
| 2019 |
Tsang J, Urner L, Tse C, Baufeld L, Faull K, Clark P, Cloughesy T, Jung M, Nathanson D. DDIS-17. DEVELOPMENT OF BRAIN-PENETRANT EGFR INHIBITORS FOR CNS MALIGNANCIES Neuro-Oncology. 21: vi66-vi66. DOI: 10.1093/Neuonc/Noz175.268 |
0.301 |
|
| 2019 |
Fernandez E, Mai W, Bayley N, Liau L, Cloughesy T, Letai A, Nathanson D. CBMT-44. COMPREHENSIVE CHARACTERIZATION OF THE INTRINSIC APOPTOTIC MACHINERY REVEALS THE MOLECULAR BLOCKS RESPONSIBLE FOR RESISTANCE TO CELL DEATH IN GLIOBLASTOMA Neuro-Oncology. 21: vi42-vi42. DOI: 10.1093/Neuonc/Noz175.166 |
0.376 |
|
| 2019 |
Mellinghoff I, Cloughesy T, Wen P, Taylor J, Maher E, Arrillaga-Romany I, Peters K, Choi C, Ellingson B, Lin A, Thakur S, Nicolay B, Lu M, Le K, Yin F, et al. ACTR-66. A PHASE 1, OPEN-LABEL, PERIOPERATIVE STUDY OF IVOSIDENIB (AG-120) AND VORASIDENIB (AG-881) IN RECURRENT IDH1 MUTANT, LOW-GRADE GLIOMA: UPDATED RESULTS Neuro-Oncology. 21: vi28-vi29. DOI: 10.1093/Neuonc/Noz175.107 |
0.433 |
|
| 2019 |
Bayley N, Tse C, Baufeld L, Gosa L, Yan W, Zhu H, Balanis N, Cloughesy T, Liau L, Graeber T, Nathanson D. TMIC-26. PRECLINICAL MODEL SYSTEMS OF GLIOBLASTOMA REVEAL MICROENVIRONMENTAL PROGRAMS AND DEPENDENCIES IN PATIENT TUMORS Neuro-Oncology. 21: vi253-vi253. DOI: 10.1093/Neuonc/Noz175.1060 |
0.4 |
|
| 2019 |
Wen P, DeGroot J, Battiste J, Goldlust S, Garner J, Simpson J, Kijlstra J, Olivero A, Cloughesy T. ACTR-64. PHASE 2 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND CLINICAL ACTIVITY OF PI3K/mTOR INHIBITOR GDC-0084 IN GBM PATIENTS WITH UNMETHYLATED O6-METHYLGUANINE-METHYLTRANSFERASE (MGMT) PROMOTER STATUS Neuro-Oncology. 21: vi28-vi28. DOI: 10.1093/Neuonc/Noz175.106 |
0.383 |
|
| 2019 |
Mochizuki A, Lee A, Orpilla J, Kienzler J, Galvez M, Chow F, Davidson T, Wang A, Everson R, Liau L, Cloughesy T, Prins R. TMIC-06. MYELOID POPULATIONS AND THE EFFECT OF NEOADJUVANT PD-1 INHIBITION IN THE GLIOBLASTOMA MICROENVIRONMENT: A SURFACEOMIC AND TRANSCRIPTOMIC DISSECTION AT THE SINGLE-CELL LEVEL Neuro-Oncology. 21: vi248-vi248. DOI: 10.1093/Neuonc/Noz175.1040 |
0.349 |
|
| 2019 |
Ahluwalia M, Dhruv H, Fallah J, Berens M, Drappatz J, Ye X, Lesser G, Cloughesy T, Walbert T, Holdhoff M, Peereboom D, Nabors L, Wen P, Grossman S, Rogers L. ACTR-43. GENOMIC ANALYSIS OF RESPONDERS OF PHASE II TRIAL OF TEMOZOLOMIDE AND TRC-102 (BASE EXCISION REPAIR INHIBITOR) IN BEVACIZUMAB-NAÏVE GLIOBLASTOMA AT FIRST RECURRENCE Neuro-Oncology. 21: vi23-vi23. DOI: 10.1093/Neuonc/Noz175.085 |
0.393 |
|
| 2019 |
Piotrowski A, Puduvalli V, Wen P, Campian J, Colman H, Pearlman M, Butowski N, Battiste J, Glass J, Cloughesy T, Schiff D, van den Bent M, Walbert T, Ahluwalia M, Badruddoja M, et al. ACTR-39. PAMIPARIB IN COMBINATION WITH RADIATION THERAPY (RT) AND/OR TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED OR RECURRENT/REFRACTORY (R/R) GLIOBLASTOMA (GBM); PHASE 1B/2 STUDY UPDATE Neuro-Oncology. 21: vi21-vi22. DOI: 10.1093/Neuonc/Noz175.081 |
0.348 |
|
| 2019 |
Arrillaga-Romany I, Kurz S, Sumrall A, Butowski N, Harrison R, DeGroot J, Chi A, Sulman E, Shonka N, Umemura Y, Odia Y, Mehta M, Iwamoto F, Leia Nghiemphu P, Cloughesy T, et al. ACTR-34. SINGLE AGENT ONC201 IN PREVIOUSLY-TREATED, PROGRESSIVE ADULT H3 K27M-MUTANT GLIOMA Neuro-Oncology. 21: vi20-vi21. DOI: 10.1093/Neuonc/Noz175.077 |
0.406 |
|
| 2019 |
Kurz S, Silverman JS, Hochman T, Nayak L, Arrillaga-Romany I, Lee E, Patel A, Delara M, Hsu F, Imtiaz T, Magnelli L, Taylor J, Cloughesy T, Sulman E, Golfinos J, et al. ATIM-37. PHASE II, OPEN-LABEL, SINGLE ARM, MULTICENTER STUDY OF AVELUMAB WITH HYPOFRACTIONATED RADIATION (HFRT) FOR ADULT PATIENTS WITH SECONDARILY TRANSFORMED IDH-MUTANT GLIOBLASTOMA (GBM) Neuro-Oncology. 21: vi9-vi10. DOI: 10.1093/Neuonc/Noz175.036 |
0.38 |
|
| 2019 |
Aiken R, Chen C, Cloughesy T, Colman H, Daras M, Groves M, Khagi S, Kumthekar P, Lang F, Nassiri F, Ong S, Ramakrishna R, Sonabend A, Vogelbaum M, Zadeh G, et al. ATIM-33. INTERIM RESULTS OF A PHASE II MULTI-CENTER STUDY OF ONCOLYTIC ADENOVIRUS DNX-2401 WITH PEMBROLIZUMAB FOR RECURRENT GLIOBLASTOMA; CAPTIVE STUDY (KEYNOTE-192) Neuro-Oncology. 21: vi8-vi9. DOI: 10.1093/Neuonc/Noz175.032 |
0.406 |
|
| 2019 |
Chow F, Mochizuki A, Lee A, Galvez M, Orpilla J, Everson R, Liau L, Cloughesy T, Prins R. ATIM-16. VALIDATION OF RESPONSE TO NEOADJUVANT ANTI-PD-1 IMMUNOTHERAPY IN RECURRENT GLIOBLASTOMA Neuro-Oncology. 21: vi4-vi5. DOI: 10.1093/Neuonc/Noz175.016 |
0.411 |
|
| 2019 |
Cloughesy T, Butowski N, Harats D, Rachmilewitz Minei T, Wen P. ATIM-09. CLINICAL TRIAL IN PROGRESS: A STUDY OF NEOADJUVANT AND ADJUVANT VB-111 FOR TREATMENT OF RECURRENT GBM Neuro-Oncology. 21: vi3-vi3. DOI: 10.1093/neuonc/noz175.009 |
0.427 |
|
| 2018 |
Kong XT, Nguyen NT, Choi YJ, Zhang G, Nguyen HN, Filka E, Green S, Yong WH, Liau LM, Green RM, Kaprealian T, Pope WB, Nghiemphu PL, Cloughesy T, Lassman A, et al. Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment. International Journal of Radiation Oncology, Biology, Physics. 100: 1195-1203. PMID 29722661 DOI: 10.1016/J.Ijrobp.2018.01.001 |
0.359 |
|
| 2018 |
Mellinghoff I, Maher E, Wen P, Cloughesy T, Peters K, Choi C, Ellingson B, Lin A, Li Y, Soher B, Young R, Steelman L, Le K, Yin F, Wu B, et al. RBTT-03. A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PERIOPERATIVE STUDY OF AG-120 (IVOSIDENIB) AND AG-881 IN PATIENTS WITH RECURRENT, NONENHANCING, IDH1-MUTANT, LOW-GRADE GLIOMA Neuro-Oncology. 20: vi234-vi234. DOI: 10.1093/Neuonc/Noy148.973 |
0.331 |
|
| 2018 |
Ligon K, Lupo J, Molinaro A, Block S, Charbonneau S, Geduldig J, Stemmer-Rachamimov A, DeAngelis L, Yong W, Schultz N, Young R, Huang R, Chang S, Arrillaga-Romany I, Alexander B, ... ... Cloughesy T, et al. PATH-08. THE IVY GLIOBLASTOMA PATIENT ATLAS - A NOVEL CLINICAL AND RADIO-GENOMICS RESOURCE FOR EARLY PHASE CLINICAL TRIAL DESIGN AND INTERPRETATION Neuro-Oncology. 20: vi159-vi159. DOI: 10.1093/Neuonc/Noy148.664 |
0.307 |
|
| 2018 |
Bayley N, Baufeld L, Gosa L, Morrow D, Tse C, Balanis N, Yan W, Cloughesy T, Liau L, Graeber T, Nathanson D. TMOD-03. GLIOMAPDOX: A MOLECULARLY DIVERSE LIBRARY OF DIRECT-FROM-PATIENT ORTHOTOPIC GLIOMA XENOGRAFTS RECAPITULATES INTRATUMOR HETEROGENEITY Neuro-Oncology. 20: vi268-vi269. DOI: 10.1093/Neuonc/Noy148.1116 |
0.358 |
|
| 2018 |
Wen P, Cloughesy T, de Groot J, Battiste J, Garner J, Simpson J, Olivero A, Gerstner E. ACTR-51. PHASE 2 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND CLINICAL ACTIVITY OF PI3K/MTOR INHIBITOR GDC-0084 GIVEN TO GLIOBLASTOMA (GBM) PATIENTS WITH UNMETHYLATED O6-METHYLGUANINE-METHYLTRANSFERASE PROMOTER STATUS Neuro-Oncology. 20: vi23-vi23. DOI: 10.1093/Neuonc/Noy148.083 |
0.385 |
|
| 2018 |
Mellinghoff I, Penas-Prado M, Peters K, Cloughesy T, Burris H, Maher E, Janku F, Cote G, De La Fuente M, Clarke J, Steelman L, Le K, Xu H, Sonderfan A, Hummel D, et al. ACTR-31. PHASE 1 STUDY OF AG-881, AN INHIBITOR OF MUTANT IDH1 AND IDH2: RESULTS FROM THE RECURRENT/PROGRESSIVE GLIOMA POPULATION Neuro-Oncology. 20: vi18-vi18. DOI: 10.1093/Neuonc/Noy148.064 |
0.305 |
|
| 2018 |
Shih K, Schiff D, Kim L, Battiste J, Campian J, Puduvalli V, Wen P, Cloughesy T, van den Bent M, Pirzkall A, Wood K, Wei R, Du B, Mu S, Ramakrishnan V, et al. ACTR-30. PHASE 1B/2 STUDY TO ASSESS THE CLINICAL EFFECTS OF PAMIPARIB (BGB-290) IN COMBINATION WITH RADIATION THERAPY (RT) AND/OR TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED OR RECURRENT/REFRACTORY GLIOBLASTOMA (GBM) Neuro-Oncology. 20: vi17-vi18. DOI: 10.1093/Neuonc/Noy148.063 |
0.401 |
|
| 2018 |
Ahluwalia M, Drappatz J, Ye X, Walbert T, Holdhoff M, Lesser G, Cloughesy T, Peereboom D, Burt Nabors L, Wen P, Grossman S, Rogers L. ACTR-18. PHASE II TRIAL OF TEMOZOLOMIDE AND TRC 102, BASE EXCISION REPAIR INHIBITOR, IN BEVACIZUMAB NAÏVE GLIOBLASTOMA AT FIRST RECURRENCE Neuro-Oncology. 20: vi15-vi15. DOI: 10.1093/Neuonc/Noy148.052 |
0.323 |
|
| 2018 |
Reardon D, Kaley T, Dietrich J, Clarke J, Dunn G, Lim M, Cloughesy T, Gan H, Park A, Schwarzenberger P, Ricciardi T, Macri M, Ryan A, Venhaus R. ATIM-38. PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB, DURVA) + BEVACIZUMAB (BEV) IN BEV-NAÏVE PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM) Neuro-Oncology. 20: vi10-vi10. DOI: 10.1093/Neuonc/Noy148.033 |
0.368 |
|
| 2018 |
Accomando W, Cloughesy T, Kalkanis S, Mikkelsen T, Landolfi J, Carter B, Chen C, Vogelbaum M, Elder J, Piccioni D, Walbert T, Hogan D, Diago O, Gammon D, Haghighi A, et al. ATIM-26. IMMUNOLOGIC TRENDS ASSOCIATED WITH PATIENT OUTCOMES IN A PHASE 1 CLINICAL TRIAL OF TOCA 511 AND TOCA FC IN RECURRENT HIGH GRADE GLIOMA Neuro-Oncology. 20: vi6-vi7. DOI: 10.1093/Neuonc/Noy148.021 |
0.37 |
|
| 2018 |
Zadeh G, Lang F, Daras M, Cloughesy T, Colman H, Ong S, Ramakrishna R, Vogelbaum M, Groves M, Nassiri F, Frederick LS, Gammon K, Fulling S, Rowland KA, Mitchell E, et al. ATIM-24. INTERIM RESULTS OF A PHASE II MULTICENTER STUDY OF THE CONDITIONALLY REPLICATIVE ONCOLYTIC ADENOVIRUS DNX-2401 WITH PEMBROLIZUMAB (KEYTRUDA) FOR RECURRENT GLIOBLASTOMA; CAPTIVE STUDY (KEYNOTE-192) Neuro-Oncology. 20: vi6-vi6. DOI: 10.1093/Neuonc/Noy148.019 |
0.393 |
|
| 2018 |
Cloughesy T, Brenner AJ, Butowski N, Cohen YC, Lowenton-Spier N, Wen P. ATIM-19. RESULTS OF THE GLOBE STUDY: A PHASE 3, RANDOMIZED, CONTROLLED, DOUBLE-ARM, OPEN-LABEL, MULTI-CENTER STUDY OF VB-111 COMBINED WITH BEVACIZUMAB VS. BEVACIZUMAB MONOTHERAPY IN PATIENTS WITH RECURRENT GLIOBLASTOMA Neuro-Oncology. 20: vi4-vi5. DOI: 10.1093/NEUONC/NOY148.014 |
0.369 |
|
| 2018 |
Mikkelsen T, Cloughesy T, Landolfi J, Vogelbaum M, Ostertag D, Elder J, Chen C, Kalkanis S, Kesari S, Lai A, Lee I, Liau L, Nghiemphu P, Piccioni D, Accomando W, et al. 25 Durable complete responses observed in patients with recurrent high grade glioma treated with Toca 511 & Toca FC Canadian Journal of Neurological Sciences / Journal Canadien Des Sciences Neurologiques. 45: S11-S11. DOI: 10.1017/Cjn.2018.290 |
0.327 |
|
| 2018 |
Zadeh G, Walbert T, Perry J, Zhu J, Salacz M, Bota D, Kim L, Iwamoto F, Petrecca K, Sully S, Montellano T, Kheoh T, Das A, Cloughesy T. 10 Toca 5: Toca 511 combined with Toca FC versus standard of care in patients undergoing planned resection for recurrent glioblastoma or anaplastic astrocytoma Canadian Journal of Neurological Sciences / Journal Canadien Des Sciences Neurologiques. 45: S2-S2. DOI: 10.1017/cjn.2018.256 |
0.333 |
|
| 2017 |
Omuro A, Vlahovic G, Lim M, Sahebjam S, Baehring J, Cloughesy T, Voloschin A, Ramkissoon SH, Ligon KL, Latek R, Zwirtes R, Strauss L, Paliwal P, Harbison CT, Reardon DA, et al. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase 1 cohorts of CheckMate 143. Neuro-Oncology. PMID 29106665 DOI: 10.1093/Neuonc/Nox208 |
0.392 |
|
| 2017 |
Wen PY, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, Chamberlain M, Mikkelsen T, Desjardins A, Holland J, Ping J, Weitzman R, Cloughesy TF. Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy. Neuro-Oncology. PMID 29016998 DOI: 10.1093/neuonc/nox154 |
0.309 |
|
| 2017 |
Nghiemphu PL, Ebiana VA, Wen P, Gilbert M, Abrey LE, Lieberman F, DeAngelis LM, Robins HI, Yung WKA, Chang S, Drappatz J, Mehta MP, Levin VA, Aldape K, Dancey JE, ... ... Cloughesy TF, et al. Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02. Journal of Neuro-Oncology. PMID 28988377 DOI: 10.1007/S11060-017-2624-4 |
0.302 |
|
| 2017 |
Antonios JP, Soto H, Everson RG, Moughon DL, Wang AC, Orpilla J, Radu C, Ellingson BM, Lee JT, Cloughesy T, Phelps ME, Czernin J, Liau LM, Prins RM. Detection of immune responses after immunotherapy in glioblastoma using PET and MRI. Proceedings of the National Academy of Sciences of the United States of America. PMID 28874539 DOI: 10.1073/Pnas.1706689114 |
0.338 |
|
| 2017 |
Ellingson BM, Gerstner E, Smits M, Huang RY, Colen RR, Abrey LE, Aftab DT, Schwab GM, Hessel C, Harris RJ, Chakhoyan A, Gahrmann R, Pope WB, Leu K, Raymond C, ... ... Cloughesy TF, et al. Diffusion MRI phenotypes predict overall survival benefitfrom anti-VEGF monotherapy in recurrent glioblastoma:Converging evidence from phase II trials. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28655794 DOI: 10.1158/1078-0432.Ccr-16-2844 |
0.3 |
|
| 2017 |
Berry DA, Graves T, Connor J, Alexander B, Cloughesy T, Barker A, Berry SM. Abstract 3594: Adaptively randomized seamless-phase multiarm platform trial: Glioblastoma Multiforme Adaptive Global Innovative Learning Environment (GBM AGILE) Cancer Research. 77: 3594-3594. DOI: 10.1158/1538-7445.Am2017-3594 |
0.366 |
|
| 2017 |
Ellingson B, Abrey L, Nelson S, Garcia J, Chinot O, Saran F, Nishikawa R, Henriksson R, Mason W, Wick W, Butowski N, Ligon K, Gerstner E, Colman H, Taylor J, ... ... Cloughesy TF, et al. NIMG-84. TUMOR LOCATION IS PROGNOSTIC FOR OVERALL SURVIVAL IN NEWLY DIAGNOSED GLIOBLASTOMA: EVIDENCE FROM 1,458 PATIENTS POOLED FROM INTERNATIONAL TRIALS, SINGLE INSTITUTION DATABASES, AND MULTICENTER CONSORTIUMS Neuro-Oncology. 19: vi161-vi161. DOI: 10.1093/Neuonc/Nox168.654 |
0.309 |
|
| 2017 |
Ellingson B, Abrey L, Nelson S, Garcia J, Chinot O, Saran F, Nishikawa R, Henriksson R, Mason W, Wick W, Butowski N, Ligon K, Gerstner E, Colman H, de Groot J, ... ... Cloughesy TF, et al. NIMG-53. POST-SURGICAL, RESIDUAL ENHANCING TUMOR VOLUME IS PROGNOSTIC FOR OVERALL SURVIVAL IN NEWLY DIAGNOSED GLIOBLASTOMA: EVIDENCE FROM 1,458 PATIENTS POOLED FROM INTERNATIONAL TRIALS, SINGLE INSTITUTION DATABASES, AND MULTICENTER CONSORTIUMS Neuro-Oncology. 19: vi154-vi154. DOI: 10.1093/Neuonc/Nox168.627 |
0.31 |
|
| 2017 |
Piedra ER, Ellingson B, El-Saden S, Cloughesy T, Taira R, Bui A, Hsu W. NIMG-08. EVALUATING THE APPLICABILITY OF TUMOR PROBABILITY MAPS AS A RESOURCE FOR IMPROVED BRAIN TUMOR SEGMENTATION Neuro-Oncology. 19: vi144-vi144. DOI: 10.1093/Neuonc/Nox168.587 |
0.328 |
|
| 2017 |
Reardon D, Desjardins A, Rixe O, Cloughesy T, Alekar S, Gamelin E, Williams J, Meissen J, Taylor C, Lassman A. ATIM-29. A PHASE 1 STUDY OF PF-06840003, AN ORAL INDOLE 2,3-DIOXYGENASE 1 (IDO1) INHIBITOR IN PATIENTS WITH MALIGNANT GLIOMAS Neuro-Oncology. 19: vi32-vi32. DOI: 10.1093/NEUONC/NOX168.123 |
0.31 |
|
| 2017 |
Ostertag D, Accomando W, Hogan D, Diago O, Gammon D, Haghighi A, Mitchell L, Rodriguez-Aquirre M, Cloughesy T, Kalkanis S, Mikkelsen T, Landolfi J, Chen C, Vogelbaum M, Gruber H, et al. ATIM-25. IMMUNOLOGICAL ACTIVATION IN RESPONDING PATIENTS WITH RECURRENT HGG AFTER TREATMENT WITH TOCA 511 & TOCA FC: RESULTS FROM A PHASE 1 TRIAL Neuro-Oncology. 19: vi31-vi32. DOI: 10.1093/Neuonc/Nox168.120 |
0.363 |
|
| 2017 |
Walbert T, Bota D, Vogelbaum M, Kalkanis S, Liau L, Mikkelsen T, Gruber H, Shorr J, Rodriguez-Aquirre M, Ostertag D, Mitchell L, Jolly D, Cloughesy T. ATIM-21. INTRAVENOUS DELIVERY OF TOCA 511 IN PATIENTS WITH HIGH GRADE GLIOMA RESULTS IN QUANTIFIABLE EXPRESSION OF CYTOSINE DEAMINASE IN TUMOR TISSUE Neuro-Oncology. 19: vi30-vi31. DOI: 10.1093/Neuonc/Nox168.116 |
0.37 |
|
| 2017 |
Walbert T, Bota D, Vogelbaum M, Kalkanis S, Liau L, Mikkelsen T, Gruber H, Shorr J, Rodriguez-Aguirre M, Ostertag D, Mitchell L, Jolly D, Cloughesy T. SCDT-06. QUANTIFIABLE LEVELS OF THE TRANSGENE, CYTOSINE DEAMINASE, IN TUMOR SAMPLES FOLLOWING INTRAVENOUS DELIVERY OF TOCA 511 IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA Neuro-Oncology. 19: vi265-vi266. DOI: 10.1093/Neuonc/Nox168.1089 |
0.389 |
|
| 2017 |
Reardon D, Kaley T, Dietrich J, Clarke JL, Dunn GP, Lim M, Cloughesy T, Gan HK, Park A, Schwarzenberger P, Ricciardi T, Macri M, Ryan A, Venhaus R. ATIM-12. PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB [DUR]) IN PATIENTS WITH BEVACIZUMAB (BEV)-REFRACTORY RECURRENT GLIOBLASTOMA (GBM) Neuro-Oncology. 19: vi28-vi28. DOI: 10.1093/Neuonc/Nox168.108 |
0.37 |
|
| 2017 |
Cloughesy T, Landolfi J, Vogelbaum M, Ostertag D, Elder B, Carter B, Chen C, Kalkanis S, Lai A, Mikkelsen T, Nghiemphu P, Piccioni D, Accomando W, Diago O, Hogan D, et al. ATIM-02. DURABLE RESPONSES OBSERVED IN IDH1 WILDTYPE AND MUTANT RECURRENT HIGH GRADE GLIOMA (rHGG) WITH TOCA 511 & TOCA FC TREATMENT Neuro-Oncology. 19: vi26-vi26. DOI: 10.1093/Neuonc/Nox168.099 |
0.432 |
|
| 2017 |
Bahng HH, Green S, Lai A, Hu J, Green R, Iwamoto F, Lassman AB, Cloughesy T, Nghiemphu P. ACTR-89. KARNOFSKY PERFORMANCE STATUS AND STEROID USE IN PHASE II TRIAL OF BEVACIZUMAB AND TEMOZOLOMIDE FOR UPFRONT TREATMENT OF ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA Neuro-Oncology. 19: vi20-vi20. DOI: 10.1093/NEUONC/NOX168.074 |
0.357 |
|
| 2016 |
Cloughesy T, Finocchiaro G, Belda-Iniesta C, Recht L, Brandes AA, Pineda E, Mikkelsen T, Chinot OL, Balana C, Macdonald DR, Westphal M, Hopkins K, Weller M, Bais C, Sandmann T, et al. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O(6)-Methylguanine-DNA Methyltransferase Biomarker Analyses. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2015647685. PMID 27918718 DOI: 10.1200/Jco.2015.64.7685 |
0.43 |
|
| 2016 |
Sulman EP, Ismaila N, Armstrong TS, Tsien C, Batchelor TT, Cloughesy T, Galanis E, Gilbert M, Gondi V, Lovely M, Mehta M, Mumber MP, Sloan A, Chang SM. Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016707562. PMID 27893327 DOI: 10.1200/Jco.2016.70.7562 |
0.331 |
|
| 2016 |
Pan E, Supko JG, Kaley TJ, Butowski NA, Cloughesy T, Jung J, Desideri S, Grossman S, Ye X, Park DM. Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma. Journal of Neuro-Oncology. PMID 27826680 DOI: 10.1007/s11060-016-2263-1 |
0.413 |
|
| 2016 |
Ellingson BM, Harris RJ, Woodworth DC, Leu K, Zaw O, Mason WP, Sahebjam S, Abrey LE, Aftab DT, Schwab GM, Hessel C, Lai A, Nghiemphu PL, Pope WB, Wen PY, ... Cloughesy TF, et al. Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single- and multicenter trials. Neuro-Oncology. PMID 27580889 DOI: 10.1093/neuonc/now187 |
0.317 |
|
| 2016 |
Wick W, Chinot OL, Bendszus M, Mason W, Henriksson R, Saran F, Nishikawa R, Revil C, Kerloeguen Y, Cloughesy T. Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma. Neuro-Oncology. PMID 27515827 DOI: 10.1093/neuonc/now091 |
0.41 |
|
| 2016 |
Cloughesy TF, Landolfi J, Hogan DJ, Bloomfield S, Carter B, Chen CC, Elder JB, Kalkanis SN, Kesari S, Lai A, Lee IY, Liau LM, Mikkelsen T, Nghiemphu PL, Piccioni D, et al. Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. Science Translational Medicine. 8: 341ra75. PMID 27252174 DOI: 10.1126/Scitranslmed.Aad9784 |
0.313 |
|
| 2016 |
Chinot OL, Nishikawa R, Mason W, Henriksson R, Saran F, Cloughesy T, Garcia J, Revil C, Abrey L, Wick W. Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio. Neuro-Oncology. PMID 27006178 DOI: 10.1093/neuonc/now046 |
0.37 |
|
| 2016 |
Rockne R, Rockhill JK, Mrugala M, Spence AM, Kalet I, Hendrickson K, Lai A, Cloughesy T, Alvord EC, Swanson KR. Reply to comment on: 'Predicting the efficacy of radiotherapy in individual glioblastoma patients in vivo: a mathematical modeling approach'. Physics in Medicine and Biology. 61: 2968-9. PMID 26988701 DOI: 10.1088/0031-9155/61/7/2968 |
0.311 |
|
| 2016 |
Chinot OL, Taphoorn MJ, Bais C, Bourgon R, Phillips HS, Abrey LE, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Cloughesy T. Reply to T.J. Kruser et al. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26884575 DOI: 10.1200/JCO.2015.65.2438 |
0.317 |
|
| 2016 |
Saran F, Chinot OL, Henriksson R, Mason W, Wick W, Cloughesy T, Dhar S, Pozzi E, Garcia J, Nishikawa R. Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy. Neuro-Oncology. PMID 26809751 DOI: 10.1093/neuonc/nov300 |
0.378 |
|
| 2016 |
Happold C, Gorlia T, Chinot O, Gilbert MR, Nabors LB, Wick W, Pugh SL, Hegi M, Cloughesy T, Roth P, Reardon DA, Perry JR, Mehta MP, Stupp R, Weller M. Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26786929 DOI: 10.1200/Jco.2015.63.6563 |
0.362 |
|
| 2016 |
Prados M, Kuhn JG, Colman H, Cloughesy TF, Chang SM, Butowski NA, De Groot JF, Wen PY, Ligon KL, Mellinghoff IK, Chi AS, Phillips JJ, Molinaro AM, Halperin R, Tran N, et al. Precision medicine in recurrent glioblastoma: A feasibility trial conducted by the Ivy Foundation Early Phase Clinical Trials Consortium. Journal of Clinical Oncology. 34: 2031-2031. DOI: 10.1200/Jco.2016.34.15_Suppl.2031 |
0.302 |
|
| 2016 |
Reardon DA, Dietrich J, Kaley T, Gan H, Dunn GP, Cloughesy T, Lim M, Clarke J, Park A, Pan L, Lai DW, Karakunnel J, Robbins P, Narwal R, Venhaus R. Abstract A046: Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 in patients with glioblastoma (GBM) Cancer Immunology Research. 4. DOI: 10.1158/2326-6074.Cricimteatiaacr15-A046 |
0.378 |
|
| 2016 |
Reardon DA, Kaley T, Dietrich J, Lim M, Dunn GP, Gan HK, Cloughesy T, Clarke JL, Park A, Macri M, Ryan A, Ricciardi T, Reddy V, Venhaus R. Abstract IA20: Phase II study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab) in patients with glioblastoma (GBM): Results for cohort B (durvalumab monotherapy), bevacizumab-naïve patients with recurrent GBM Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-Ia20 |
0.425 |
|
| 2016 |
Pham J, Abe C, Bahng HH, Sevilla J, Fong N, Lai A, Cloughesy T, Nghiemphu P. QLIF-09. A FOCUS ON THE PSYCHOSOCIAL NEEDS OF OLDER BRAIN TUMOR PATIENTS Neuro-Oncology. 18: vi158-vi158. DOI: 10.1093/NEUONC/NOW212.655 |
0.358 |
|
| 2016 |
Ellingson B, Abrey L, Garcia J, Chinot O, Aftab D, Schwab G, Revil C, Saran F, Nishikawa R, Henriksson R, Hessel C, Harris R, Woodworth D, Leu K, Lai A, ... ... Cloughesy T, et al. NIMG-31. RESIDUAL ENHANCING TUMOR VOLUME IS A STRONG PROGNOSTIC BIOMARKER FOR SURVIVAL IN BOTH NEWLY DIAGNOSED AND RECURRENT GBM REGARDLESS OF THERAPY: EVIDENCE FROM 1,535 PATIENTS IN SINGLE AND MULTICENTER TRIALS Neuro-Oncology. 18: vi131-vi131. DOI: 10.1093/Neuonc/Now212.543 |
0.435 |
|
| 2016 |
Ostertag D, Cloughesy T, Kalkanis S, Mikkelsen T, Landolfi J, Carter B, Chen C, Das A, Jolly D, Gruber H, Vogelbaum M. ATIM-17. INVESTIGATION OF ANTI-TUMOR CELLULAR IMMUNE RESPONSE ELICITED BY TOCA 511 & TOCA FC THERAPY IN A RECURRENT HGG PHASE 1 TRIAL Neuro-Oncology. 18: vi21-vi21. DOI: 10.1093/Neuonc/Now212.082 |
0.365 |
|
| 2016 |
Omuro A, Vlahovic G, Baehring J, Butowski NA, Reardon DA, Cloughesy T, Sahebjam S, Lim M, Strauss L, Latek R, Zwirtes R, Paliwal P, Harbison C, Sampson J. ATIM-16. NIVOLUMAB COMBINED WITH RADIOTHERAPY WITH OR WITHOUT TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA: RESULTS FROM PHASE 1 SAFETY COHORTS IN CHECKMATE 143 Neuro-Oncology. 18: vi21-vi21. DOI: 10.1093/Neuonc/Now212.081 |
0.374 |
|
| 2016 |
Aghi M, Vogelbaum M, Kalkanis S, Bota D, Carter B, Chen C, Elder B, Engh J, Goldlust S, Kaptain G, Kesari S, Landolfi J, Liau L, Mikkelsen T, Piccioni D, ... ... Cloughesy T, et al. ATIM-05. COMPLEMENTARY CLINICAL AND ANCILLARY DATA FROM 123 PATIENTS WITH RECURRENT HIGH GRADE GLIOMA FROM THREE PHASE 1 TRIALS OF TOCA 511 AND TOCA FC: UPDATE AND JUSTIFICATION FOR A PHASE 2/3 TRIAL Neuro-Oncology. 18: vi18-vi18. DOI: 10.1093/Neuonc/Now212.070 |
0.359 |
|
| 2016 |
Reardon D, Kaley T, Dietrich J, Lim M, Dunn G, Gan H, Cloughesy T, Clarke J, Park A, Macri M, Ryan A, Ricciardi T, Reddy V, Venhaus R. ATIM-04. PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB [DUR]) IN PATIENTS WITH GLIOBLASTOMA (GBM): RESULTS FOR COHORT B (DUR MONOTHERAPY), BEVACIZUMAB (BEV) NAÏVE PATIENTS WITH RECURRENT GBM Neuro-Oncology. 18: vi18-vi18. DOI: 10.1093/Neuonc/Now212.069 |
0.385 |
|
| 2016 |
Cloughesy T, Walbert T, Bota D, Vogelbaum M, Liau L, Ostertag D, Jolly D, Gruber H, Yang L, Shorr J, Kalkanis S. ATIM-02. SUCCESSFUL CANCER-SELECTIVE GENE DELIVERY FOLLOWING INTRAVENOUS TOCA 511 DELIVERY IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA (HGG) Neuro-Oncology. 18: vi17-vi17. DOI: 10.1093/Neuonc/Now212.067 |
0.32 |
|
| 2016 |
Zadeh G, Bota D, Cachia D, Landolfi J, Schiff D, Vogelbaum M, Walbert T, Tran D, Chu A, Das A, Jolly D, Ibañez C, Ostertag D, Sully S, Cloughesy T. PC3 - 151 Toca 5: A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined with Toca FC versus Standard of Care in Patients Undergoing Planned Resection for Recurrent Glioblastoma (GBM) or Anaplastic Astrocytoma (AA) (NCT02414165) Canadian Journal of Neurological Sciences / Journal Canadien Des Sciences Neurologiques. 43: S17-S17. DOI: 10.1017/cjn.2016.379 |
0.339 |
|
| 2016 |
Jolly DJ, Robbins JM, Ostertag D, Ibañez C, Kasahara N, Gruber H, Kalkanis SN, Vogelbaum M, Aghi MK, Cloughesy T, Chu A, Das A, Skillings J. 61. Ascending Dose Trials of a Retroviral Replicating Vector (Toca 511) in Patients with Recurrent High-Grade Glioma: Clinical Update, Molecular Analyses, and Proposed Mechanism of Action Molecular Therapy. 24: S27. DOI: 10.1016/S1525-0016(16)32870-2 |
0.43 |
|
| 2015 |
Chang W, Pope WB, Harris RJ, Hardy AJ, Leu K, Mody RR, Nghiemphu PL, Lai A, Cloughesy TF, Ellingson BM. Diffusion MR Characteristics Following Concurrent Radiochemotherapy Predicts Progression-Free and Overall Survival in Newly Diagnosed Glioblastoma. Tomography : a Journal For Imaging Research. 1: 37-43. PMID 26740971 DOI: 10.18383/j.tom.2015.00115 |
0.305 |
|
| 2015 |
Schiff D, Desjardins A, Cloughesy T, Mikkelsen T, Glantz M, Chamberlain MC, Reardon DA, Wen PY. Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas. Cancer. PMID 26588662 DOI: 10.1002/cncr.29798 |
0.403 |
|
| 2015 |
Sandmann T, Bourgon R, Garcia J, Li C, Cloughesy T, Chinot OL, Wick W, Nishikawa R, Mason W, Henriksson R, Saran F, Lai A, Moore N, Kharbanda S, Peale F, et al. Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26124478 DOI: 10.1200/JCO.2015.61.5005 |
0.421 |
|
| 2015 |
Taphoorn MJ, Henriksson R, Bottomley A, Cloughesy T, Wick W, Mason WP, Saran F, Nishikawa R, Hilton M, Theodore-Oklota C, Ravelo A, Chinot OL. Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 2166-75. PMID 26014298 DOI: 10.1200/JCO.2014.60.3217 |
0.343 |
|
| 2015 |
Hathout L, Ellingson BM, Cloughesy T, Pope WB. A novel bicompartmental mathematical model of glioblastoma multiforme. International Journal of Oncology. 46: 825-32. PMID 25384756 DOI: 10.3892/ijo.2014.2741 |
0.321 |
|
| 2015 |
Aghi M, Vogelbaum MA, Cloughesy T, Kaptain G, Portnow J, Ostertag D, Keller MR, Niethammer A, Chu A, Kesari S. SURG-10TRANSCRANIAL TOCA 511 FOLLOWED BY TOCA FC IN SUBJECTS WITH RECURRENT HIGH GRADE GLIOMA (HGG) Neuro-Oncology. 17: v216.2-v216. DOI: 10.1093/Neuonc/Nov235.10 |
0.392 |
|
| 2015 |
Sevilla J, Abe C, Banerjee P, Fong N, Lai A, Cloughesy T, Nghiemphu P. PCSM-09PSYCHOSOCIAL AND SYMPTOMATIC SCREENING AMONG PATIENTS WITH CENTRAL NERVOUS SYSTEM TUMORS Neuro-Oncology. 17: v177.4-v178. DOI: 10.1093/NEUONC/NOV227.09 |
0.345 |
|
| 2015 |
Patel C, Nguyen H, Manoukian J, Ellingson B, Czernin J, Cloughesy T, Nghiemphu P, Lai A. NIMG-57QUANTITATION OF 18F-DOPA UPTAKE ON PET PREDICTS TUMOR GRADE WITH HIGH SENSITIVITY AND SPECIFICITY IN NEWLY-DIAGNOSED GLIOMA: UCLA EXPERIENCE Neuro-Oncology. 17: v167.1-v167. DOI: 10.1093/Neuonc/Nov225.57 |
0.378 |
|
| 2015 |
Omuro A, Baehring J, Sahebjam S, Vlahovic G, Voloschin A, Young R, Hayes W, Latek R, Coric V, Cloughesy T, Lim M, Sampson J, Reardon DA. NIMG-18EVALUATING TUMOR PROGRESSION AND IMMUNOLOGIC REACTIONS DURING IMMUNOTHERAPY: NEUROIMAGING OBSERVATIONS FROM A MULTICENTER STUDY OF NIVOLUMAB MONOTHERAPY AND NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN RECURRENT GLIOBLASTOMA (CHECKMATE-143) Neuro-Oncology. 17: v157.1-v157. DOI: 10.1093/Neuonc/Nov225.18 |
0.385 |
|
| 2015 |
Ramkissoon S, Sampson J, Vlahovic G, Sahebjam S, Omuro A, Baehring J, Latek R, Vandeloise E, Coric V, Cloughesy T, Lim M, Reardon D, Ligon K. NIMG-17CENTRAL NEUROPATHOLOGY REVIEW TO ASSIST IN THE EVALUATION OF IMMUNE-RELATED TREATMENT CHANGES VERSUS DISEASE PROGRESSION IN CHECKMATE-143 Neuro-Oncology. 17: v156.4-v157. DOI: 10.1093/Neuonc/Nov225.17 |
0.4 |
|
| 2015 |
Sahebjam S, Omuro A, Baehring J, Sampson J, Vlahovic G, Voloschin A, Hayes W, Latek R, Coric V, Cloughesy T, Lim M, Reardon DA. NIMG-16PSEUDOPROGRESSION AND IMMUNOTHERAPY IN GLIOBLASTOMA: A CASE SERIES FROM COHORT 1 OF CHECKMATE-143 (NCT02017717) Neuro-Oncology. 17: v156.3-v156. DOI: 10.1093/Neuonc/Nov225.16 |
0.359 |
|
| 2015 |
Kesari S, Landolfi J, Mikkelsen T, Aghi M, Vogelbaum MA, Elder JB, Cobbs C, Singer S, Robbins JM, Ostertag D, Jolly DJ, Chu A, Keller MR, Niethammer A, Cloughesy TF. IMCT-05COMBINABILITY OF TOCA FC AND TOCA 511 WITH CHEMOTHERAPY AND TARGETED AGENTS Neuro-Oncology. 17: v108.1-v108. DOI: 10.1093/Neuonc/Nov218.05 |
0.317 |
|
| 2015 |
Zadeh G, Vogelbaum MA, Ostertag D, Le T, Chu A, Niethammer A, Das A, Cloughesy T. IMCT-04TOCA 5: PHASE 2/3 RANDOMIZED, OPEN-LABEL STUDY OF TOCA 511 WITH TOCA FC VERSUS STANDARD OF CARE IN PATIENTS UNDERGOING PLANNED RESECTION FOR RECURRENT HIGH GRADE GLIOMA (NCT02414165) Neuro-Oncology. 17: v107.4-v108. DOI: 10.1093/NEUONC/NOV218.04 |
0.447 |
|
| 2015 |
Sampson J, Omuro A, Vlahovic G, Sahebjam S, Baehring J, Hafler DA, Voloschin A, Simon J, Latek R, Coric V, Cloughesy T, Lim M, Reardon D. IMCT-03SAFETY AND ACTIVITY OF NIVOLUMAB MONOTHERAPY AND NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN RECURRENT GLIOBLASTOMA: UPDATED RESULTS FROM CHECKMATE-143 Neuro-Oncology. 17: v107.3-v107. DOI: 10.1093/Neuonc/Nov218.03 |
0.436 |
|
| 2015 |
Ostertag D, Hogan D, Vogelbaum M, Kesari S, Kalkanis S, Mikkelsen T, Landolfi J, Elder JB, Chen C, Niethammer A, Chu A, Jolly D, Gruber H, Cloughesy T. GENO-30DISTINCT GENE EXPRESSION PROFILE THAT IS NOT A KNOWN SURVIVAL PREDICTOR IN TUMORS FROM LONG-TERM HIGH GRADE GLIOMA SURVIVORS TREATED WITH A RETROVIRAL REPLICATING VECTOR ENCODING YEAST CYTOSINE DEAMINASE Neuro-Oncology. 17: v98.2-v98. DOI: 10.1093/Neuonc/Nov215.30 |
0.399 |
|
| 2015 |
Liu F, Chowdhury R, Li T, Li S, Nguyen H, Wei B, Chou AP, Reiss JK, Mody RR, Liau LM, Nghiemphu PL, Yong WH, Cloughesy T, Lai A. EPIG-11THE IMPLICATION OF CpG island AND SPINT2 HYPERMETHYLATION IN BOTH IDH1 WILD-TYPE AND MUTANT ADULT DIFFUSE GLIOMAS Neuro-Oncology. 17: v88.3-v88. DOI: 10.1093/Neuonc/Nov214.11 |
0.309 |
|
| 2015 |
Landolfi J, Cloughesy T, Vogelbaum MA, Kesari S, Piccioni DE, Kalkanis SN, Portnow J, Mikkelsen T, Elder JB, Baskin D, Chu A, Niethammer A, Gruber H, Cobbs C, Foltz G, et al. DDEL-08OVERALL SAFETY AND EFFICACY IN SUBJECTS WITH RECURRENT HGG TREATED ACROSS 2 TOCAGEN STUDIES - PROGNOSTIC FACTORS ASSOCIATED WITH SURVIVAL Neuro-Oncology. 17: v74.4-v75. DOI: 10.1093/Neuonc/Nov212.08 |
0.453 |
|
| 2015 |
Cloughesy T, Vogelbaum MA, Ostertag D, Diego O, Jolly DJ, Ibanez C, Yagiz K, Robbins J, Chu A, Niethammer A, Gruber H, Kalkanis SN. DDEL-07INTRAVENOUS TOCA 511 DELIVERY LEADS TO VIRAL DNA IN RESECTED HGG Neuro-Oncology. 17: v74.3-v74. DOI: 10.1093/NEUONC/NOV212.07 |
0.374 |
|
| 2015 |
Lowther DE, Weinhold K, Reap E, Vlahovic G, Omuro A, Sahebjam S, Baehring J, Voloschin A, Cloughesy T, Lim M, Coric V, Latek R, Simon J, Lerner B, Raddassi K, et al. CBM-06IMMUNE BIOMARKER RESULTS FROM A TRIAL OF NIVOLUMAB ± IPILIMUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA: CHECKMATE-143 Neuro-Oncology. 17: v70.2-v70. DOI: 10.1093/Neuonc/Nov211.06 |
0.417 |
|
| 2015 |
Happold C, Gorlia T, Chinot O, Gilbert M, Nabors B, Wick W, Pugh SL, Hegi M, Cloughesy T, Roth P, Reardon D, Perry JR, Mehta M, Stupp R, Weller M. ATNT-10DOES VALPROIC ACID IMPROVE SURVIVAL IN GLIOBLASTOMA? A META-ANALYSIS OF RANDOMIZED TRIALS IN NEWLY DIAGNOSED GLIOBLASTOMA Neuro-Oncology. 17: v12.2-v12. DOI: 10.1093/Neuonc/Nov205.10 |
0.337 |
|
| 2015 |
Happold C, Gorlia T, Chinot O, Gilbert M, Nabors L, Wick W, Pugh S, Hegi M, Cloughesy T, Roth P, Reardon D, Perry J, Mehta M, Stupp R, Weller M. 26LBA Does valproic acid improve survival in glioblastoma? A meta-analysis of randomized trials in newly diagnosed glioblastoma European Journal of Cancer. 51: S723. DOI: 10.1016/S0959-8049(15)30075-7 |
0.322 |
|
| 2014 |
Baldock AL, Ahn S, Rockne R, Johnston S, Neal M, Corwin D, Clark-Swanson K, Sterin G, Trister AD, Malone H, Ebiana V, Sonabend AM, Mrugala M, Rockhill JK, Silbergeld DL, ... ... Cloughesy T, et al. Patient-specific metrics of invasiveness reveal significant prognostic benefit of resection in a predictable subset of gliomas. Plos One. 9: e99057. PMID 25350742 DOI: 10.1371/Journal.Pone.0099057 |
0.443 |
|
| 2014 |
Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. The New England Journal of Medicine. 370: 709-22. PMID 24552318 DOI: 10.1056/NEJMoa1308345 |
0.384 |
|
| 2014 |
Wen PY, Chang SM, Lamborn KR, Kuhn JG, Norden AD, Cloughesy TF, Robins HI, Lieberman FS, Gilbert MR, Mehta MP, Drappatz J, Groves MD, Santagata S, Ligon AH, Yung WK, et al. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro-Oncology. 16: 567-78. PMID 24470557 DOI: 10.1093/Neuonc/Not247 |
0.324 |
|
| 2014 |
Herrmann K, Czernin J, Cloughesy T, Lai A, Pomykala KL, Benz MR, Buck AK, Phelps ME, Chen W. Comparison of visual and semiquantitative analysis of 18F-FDOPA-PET/CT for recurrence detection in glioblastoma patients. Neuro-Oncology. 16: 603-9. PMID 24305722 DOI: 10.1093/Neuonc/Not166 |
0.348 |
|
| 2014 |
Huse JT, Wallace M, Aldape KD, Berger MS, Bettegowda C, Brat DJ, Cahill DP, Cloughesy T, Haas-Kogan DA, Marra M, Miller CR, Nelson SJ, Salama SR, Soffietti R, Wen PY, et al. Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) low-grade glioma research workshop. Neuro-Oncology. 16: 173-8. PMID 24305708 DOI: 10.1093/Neuonc/Not229 |
0.368 |
|
| 2014 |
Robbins JM, Huang TT, Jolly DJ, Kasahara N, Aghi MK, Vogelbaum MA, Cloughesy TF, Chang SM, Kesari S, Mikkelsen T, Kalkanis SN, Landolfi JC, Elder JB, Chiocca EA, Gruber HE, et al. Ascending dose trials of a retroviral replicating vector (Toca 511) in patients with recurrent high-grade glioma. Journal of Clinical Oncology. 32: 3078-3078. DOI: 10.1200/Jco.2014.32.15_Suppl.3078 |
0.311 |
|
| 2014 |
Butowski NA, Colman H, De Groot JF, Omuro AMP, Nayak L, Cloughesy TF, Marimuthu A, Perry A, Phillips JJ, West B, Prados M, Nolop KB, Hsu HH, Ligon KL. A phase 2 study of orally administered PLX3397 in patients with recurrent glioblastoma. Journal of Clinical Oncology. 32: 2023-2023. DOI: 10.1200/Jco.2014.32.15_Suppl.2023 |
0.326 |
|
| 2014 |
Huang RY, Rahman R, Pope WB, Ellingson BM, Anderson SK, Felten SJ, Ballman KV, Wu W, Nayak L, Lee EQ, Abrey LE, Galanis E, Reardon DA, Cloughesy TF, Wen PY. Validation of rano criteria: Contribution of T2/FLAIR assessment in patients with recurrent glioblastoma treated with bevacizumab. Journal of Clinical Oncology. 32: 2007-2007. DOI: 10.1200/Jco.2014.32.15_Suppl.2007 |
0.304 |
|
| 2014 |
Nghiemphu PL, Lai A, Cloughesy T. SP-02 * PATTERNS OF END-OF-LIFE CARE FOR PATIENTS WITH GLIOBLASTOMA Neuro-Oncology. 16: v211-v211. DOI: 10.1093/NEUONC/NOU276.2 |
0.315 |
|
| 2014 |
Banerjee P, Cloughesy T, Pham J, Cervantes S, Nghiemphu P, Lai A, Wellisch D. Ql-05Self-Reported Cognitive Difficulties And Associated Medical Characteristics In Patients With Adult-Onset Glioma Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou269.5 |
0.314 |
|
| 2014 |
Banerjee P, Cloughesy T, Cervantes S, Pham J, Nghiemphu P, Lai A, Wellisch D. QL-04 * FACTORS ASSOCIATED WITH SUICIDAL IDEATION IN CLINICALLY DISTRESSED ADULT GLIOMA PATIENTS Neuro-Oncology. 16: v178-v179. DOI: 10.1093/NEUONC/NOU269.4 |
0.326 |
|
| 2014 |
Schwarzenberg J, Czernin J, Cloughesy T, Lai A, Phelps M, Chen W. NI-68 * 18F-FDOPA PET IN TREATED LOW-GRADE GLIOMAS WITH NON-ENHANCING T2 CHANGES ON MRI IS PROGNOSTIC OF TUMOR PROGRESSION AND OVERALL SURVIVAL Neuro-Oncology. 16: v153-v153. DOI: 10.1093/Neuonc/Nou264.66 |
0.393 |
|
| 2014 |
Leu K, Tran A, Pope W, Lai A, Nghiemphu P, Harris R, Woodworth D, Cloughesy T, Ellingson B. NI-55 * PARAMETRIC MAPS OF CONTRAST AGENT DIFFUSION USING A NOVEL DIFFUSION-PERFUSION MODEL APPLIED TO DCE-MRI CAN DIFFERENTIATE NON-ENHANCING TUMOR FROM EDEMA IN HUMAN GLIOBLASTOMA Neuro-Oncology. 16: v150-v150. DOI: 10.1093/Neuonc/Nou264.53 |
0.322 |
|
| 2014 |
Leu K, Enzmann D, Woodworth D, Teixeira S, Lai A, Nghiemphu P, Pope W, Cloughesy T, Ellingson B. NI-54 * HYPERVASCULAR VOLUME ESTIMATED BY COMPARISON TO A LARGE-SCALE CEREBRAL BLOOD VOLUME (CBV) RADIOGRAPHIC ATLAS PREDICTS SURVIVAL IN RECURRENT GLIOBLASTOMA TREATED WITH BEVACIZUMAB Neuro-Oncology. 16: v150-v150. DOI: 10.1093/Neuonc/Nou264.52 |
0.391 |
|
| 2014 |
Huang R, Rahman R, Pope W, Ellingson B, Ballman K, Felton S, Anderson SK, Nayak L, Lee E, Abrey L, Galanis E, Reardon D, Cloughesy T, Wen P. NI-36 * VALIDATION OF RANO CRITERIA: CONTRIBUTION OF T2/FLAIR ASSESSMENT IN PATIENTS WITH RECURRENT GLIOBLASTOMA TREATED WITH BEVACIZUMAB Neuro-Oncology. 16: v145-v146. DOI: 10.1093/Neuonc/Nou264.34 |
0.396 |
|
| 2014 |
Hardy A, Prins R, Kong X, Woodworth D, Pope W, Yong W, Cloughesy T, Liau L, Ellingson B. NI-32 * ENHANCING TUMOR RESPONSE USING QUANTITATIVE VOLUMETRY FROM T1 SUBTRACTION MAPS IN MALIGNANT GLIOMA TREATED WITH DENDRITIC CELL VACCINATION Neuro-Oncology. 16: v145-v145. DOI: 10.1093/Neuonc/Nou264.30 |
0.384 |
|
| 2014 |
Ellingson B, Pope W, Nghiemphu P, Lai A, Cloughesy T. NI-22 * NON-ENHANCING TUMOR RESPONSE USING QUANTITATIVE T2 MAPS PREDICTS SURVIVAL IN GLIOBLASTOMA TREATED WITH BEVACIZUMAB Neuro-Oncology. 16: v142-v143. DOI: 10.1093/Neuonc/Nou264.21 |
0.349 |
|
| 2014 |
Ellingson B, Kim G, Woodworth D, Pope W, Nghiemphu P, Lai A, Cloughesy T. NI-21 * CONTRAST ENHANCED T1 SUBTRACTION MAPS IMPROVE DETECTION OF RESIDUAL TUMOR FOLLOWING RESECTION, REDUCES MEASUREMENT VARIABILITY, AND PREDICTS SURVIVAL AFTER ANTI-ANGIOGENIC THERAPY IN GLIOBLASTOMA Neuro-Oncology. 16: v142-v142. DOI: 10.1093/Neuonc/Nou264.20 |
0.366 |
|
| 2014 |
Ellingson B, Chang W, Harris R, Mody R, Lai A, Nghiemphu P, Cloughesy T, Pope W. NI-20 * ADC HISTOGRAM ANALYSIS FOLLOWING RADIOTHERAPY PREDICTS RESPONSE TO ADJUVANT TEMOZOLOMIDE IN NEWLY DIAGNOSED GBM Neuro-Oncology. 16: v142-v142. DOI: 10.1093/Neuonc/Nou264.19 |
0.431 |
|
| 2014 |
Cloughesy TF, Kesari S, Kalkanis S, Mikkelsen T, Landolfi J, Elder JB, Liau LM, Chen CC, Bloomfield S, Piccioni D, Chiocca EA, Foltz G, Robbins JM, Ostertag D, Jolly DJ, et al. IT-05 * ADMINISTRATION OF TOCA 511 TO SUBJECTS WITH RECURRENT HGG UNDERGOING REPEAT RESECTION Neuro-Oncology. 16: v110-v111. DOI: 10.1093/Neuonc/Nou258.4 |
0.332 |
|
| 2014 |
Schaff LR, Lassman AB, Goldlust SA, Cloughesy T, Singer S, Schwartz GK, Iwamoto FM. ET-53 * IPILIMUMAB FOR RECURRENT GLIOBLASTOMA (GBM) Neuro-Oncology. 16: v90-v90. DOI: 10.1093/NEUONC/NOU255.50 |
0.444 |
|
| 2014 |
Cloughesy T, Finocchiaro G, Belda-Iniesta C, Recht L, Brandes AA, Pineda E, Mikkelsen T, Chinot O, Balana C, Macdonald D, Westphal M, Hopkins K, Weller M, Bruey J, Liu B, et al. ET-12 * PHASE II STUDY OF ONARTUZUMAB PLUS BEVACIZUMAB VERSUS PLACEBO PLUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA Neuro-Oncology. 16: v81-v81. DOI: 10.1093/Neuonc/Nou255.12 |
0.419 |
|
| 2014 |
Phillips H, Sandmann T, Li C, Cloughesy T, Chinot OL, Wick W, Nishikawa R, Mason W, Henriksson R, Saran F, Lai A, Moore N, Hegde P, Abrey L, Bourgon R, et al. BI-22 * CORRELATION OF MOLECULAR SUBTYPES WITH OVERALL SURVIVAL (OS) IN AVAGLIO, A RANDOMIZED, PLACEBO-CONTROLLED STUDY OF BEVACIZUMAB (BEV) PLUS RADIOTHERAPY (RT) AND TEMOZOLOMIDE (TMZ) FOR NEWLY DIAGNOSED GLIOBLASTOMA (GBM) Neuro-Oncology. 16: v28-v28. DOI: 10.1093/NEUONC/NOU239.22 |
0.454 |
|
| 2014 |
Harris R, Cloughesy T, Liau L, Lai A, Nghiemphu P, Li D, Pope W, Ellingson B. BI-10 * pH-WEIGHTED MRI IN HUMAN GLIOMAS Neuro-Oncology. 16: v25-v25. DOI: 10.1093/Neuonc/Nou239.10 |
0.345 |
|
| 2014 |
Cloughesy T, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Revil C, Abrey L, Chinot OL. AT-18 * SURVIVAL ANALYSIS OF PATIENTS WITH A PFS EVENT WHO DID NOT RECEIVE POST-PROGRESSION THERAPY IN AVAGLIO (BEVACIZUMAB [BEV] PLUS RADIOTHERAPY [RT] AND TEMOZOLOMIDE [TMZ] FOR NEWLY DIAGNOSED GLIOBLASTOMA [GBM]) Neuro-Oncology. 16: v12-v12. DOI: 10.1093/NEUONC/NOU237.18 |
0.392 |
|
| 2014 |
Wen PY, Wen PY, Yung WKA, Mellinghoff IK, Ramkissoon S, Alexander B, Rinne M, Colman H, Omuro AM, DeAngelis LM, Gilbert MR, DeGroot J, Cloughesy TF, Lee EQ, Nayak L, et al. PHASE II TRIAL OF THE PHOSPHATIDYINOSITOL-3 KINASE (PI3K) INHIBITOR BUPARLISIB (BKM120) IN RECURRENT GLIOBLASTOMA CONDUCTED BY THE IVY FOUNDATION EARLY PHASE CLINICAL TRIALS CONSORTIUM Neuro-Oncology. 16: iii47-iii47. DOI: 10.1093/Neuonc/Nou209.20 |
0.364 |
|
| 2014 |
Kang J, Selch MT, Kupelian P, Cloughesy T, Lee P. High-Dose Radiation to the Subventricular Zone Does Not Alter the Patterns of Recurrence in GB International Journal of Radiation Oncology Biology Physics. 90. DOI: 10.1016/J.Ijrobp.2014.05.991 |
0.323 |
|
| 2013 |
Lee P, Eppinga W, Lagerwaard F, Cloughesy T, Slotman B, Nghiemphu PL, Wang PC, Kupelian P, Agazaryan N, Demarco J, Selch MT, Steinberg M, Kang JJ. Evaluation of high ipsilateral subventricular zone radiation therapy dose in glioblastoma: a pooled analysis. International Journal of Radiation Oncology, Biology, Physics. 86: 609-15. PMID 23462418 DOI: 10.1016/J.Ijrobp.2013.01.009 |
0.35 |
|
| 2013 |
Phillips JJ, Aranda D, Ellison DW, Judkins AR, Croul SE, Brat DJ, Ligon KL, Horbinski C, Venneti S, Zadeh G, Santi M, Zhou S, Appin CL, Sioletic S, Sullivan LM, ... ... Cloughesy T, et al. PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma. Brain Pathology (Zurich, Switzerland). 23: 565-73. PMID 23438035 DOI: 10.1111/Bpa.12043 |
0.326 |
|
| 2013 |
Neal ML, Trister AD, Cloke T, Sodt R, Ahn S, Baldock AL, Bridge CA, Lai A, Cloughesy TF, Mrugala MM, Rockhill JK, Rockne RC, Swanson KR. Discriminating survival outcomes in patients with glioblastoma using a simulation-based, patient-specific response metric. Plos One. 8: e51951. PMID 23372647 DOI: 10.1371/Journal.Pone.0051951 |
0.327 |
|
| 2013 |
Shonka N, Piao Y, Gilbert M, Yung A, Chang S, DeAngelis LM, Lassman AB, Liu J, Cloughesy T, Robins HI, Lloyd R, Chen A, Prados M, Wen PY, Heymach J, et al. Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept. Targeted Oncology. 8: 117-25. PMID 23345034 DOI: 10.1007/s11523-013-0254-0 |
0.304 |
|
| 2013 |
Weller M, Cloughesy T, Perry JR, Wick W. Standards of care for treatment of recurrent glioblastoma--are we there yet? Neuro-Oncology. 15: 4-27. PMID 23136223 DOI: 10.1093/neuonc/nos273 |
0.403 |
|
| 2013 |
Li S, Chou AP, Chen W, Chen R, Deng Y, Phillips HS, Selfridge J, Zurayk M, Lou JJ, Everson RG, Wu KC, Faull KF, Cloughesy T, Liau LM, Lai A. Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation. Neuro-Oncology. 15: 57-68. PMID 23115158 DOI: 10.1093/Neuonc/Nos261 |
0.32 |
|
| 2013 |
Wen PY, Yung WKA, Mellinghoff IK, Lamborn K, Ramkissoon S, Cloughesy TF, Rinne M, Omuro AMP, DeAngelis LM, Gilbert MR, Chi AS, Batchelor T, Colman H, Chang SM, Massacesi C, et al. Phase II trial of the phosphatidyinositol-3 kinase (PI3K) inhibitor BKM120 in recurrent glioblastoma (GBM). Journal of Clinical Oncology. 31: 2015-2015. DOI: 10.1200/Jco.2013.31.15_Suppl.2015 |
0.358 |
|
| 2013 |
Cloughesy TF, Mischel PS, Omuro AMP, Prados M, Wen PY, Wu B, Rockich K, Xu Y, Lager JJ, Mellinghoff IK. Tumor pharmacokinetics (PK) and pharmacodynamics (PD) of SAR245409 (XL765) and SAR245408 (XL147) administered as single agents to patients with recurrent glioblastoma (GBM): An Ivy Foundation early-phase clinical trials consortium study. Journal of Clinical Oncology. 31: 2012-2012. DOI: 10.1200/jco.2013.31.15_suppl.2012 |
0.318 |
|
| 2013 |
Wick W, Cloughesy T, Mason W, Henriksson R, Saran F, Nishikawa R, Hilton M, Garcia J, Pallaud C, Chinot O. Efficacy and biomarker findings from AVaglio, a phase III trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma Journal of the Neurological Sciences. 333. DOI: 10.1016/J.Jns.2013.07.2268 |
0.393 |
|
| 2013 |
Saran F, Henriksson R, Mason W, Wick W, Nishikawa R, Cloughesy T, Hilton M, Kerloeguen Y, Chinot O. The Addition of Bevacizumab (BEV) to Temozolomide (TMZ) and Radiation Therapy (RT) in Newly Diagnosed Glioblastoma (GBM) Improves Progression-Free Survival (PFS) Without Adding to RT Toxicity International Journal of Radiation Oncology*Biology*Physics. 87: S16. DOI: 10.1016/J.IJROBP.2013.06.047 |
0.326 |
|
| 2012 |
Chou AP, Chowdhury R, Li S, Chen W, Kim AJ, Piccioni DE, Selfridge JM, Mody RR, Chang S, Lalezari S, Lin J, Sanchez DE, Wilson RW, Garrett MC, Harry B, ... ... Cloughesy T, et al. Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas. Journal of the National Cancer Institute. 104: 1458-69. PMID 22945948 DOI: 10.1093/Jnci/Djs357 |
0.383 |
|
| 2012 |
Nghiemphu PL, Lai A, Green RM, Reardon DA, Cloughesy T. A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas. Journal of Neuro-Oncology. 110: 245-50. PMID 22918789 DOI: 10.1007/s11060-012-0960-y |
0.379 |
|
| 2012 |
Piccioni D, Lai A, Nghiemphu P, Cloughesy T. Bevacizumab as first-line therapy for glioblastoma. Future Oncology (London, England). 8: 929-38. PMID 22894667 DOI: 10.2217/fon.12.81 |
0.372 |
|
| 2012 |
Trippa L, Lee EQ, Wen PY, Batchelor TT, Cloughesy T, Parmigiani G, Alexander BM. Bayesian adaptive randomized trial design for patients with recurrent glioblastoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 3258-63. PMID 22649140 DOI: 10.1200/JCO.2011.39.8420 |
0.349 |
|
| 2012 |
Galanis E, Wu W, Cloughesy T, Lamborn K, Mann B, Wen PY, Reardon DA, Wick W, Macdonald D, Armstrong TS, Weller M, Vogelbaum M, Colman H, Sargent DJ, van den Bent MJ, et al. Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. The Lancet. Oncology. 13: e196-204. PMID 22554547 DOI: 10.1016/S1470-2045(11)70406-5 |
0.326 |
|
| 2012 |
Pope WB, Qiao XJ, Kim HJ, Lai A, Nghiemphu P, Xue X, Ellingson BM, Schiff D, Aregawi D, Cha S, Puduvalli VK, Wu J, Yung WK, Young GS, Vredenburgh J, ... ... Cloughesy T, et al. Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. Journal of Neuro-Oncology. 108: 491-8. PMID 22426926 DOI: 10.1007/s11060-012-0847-y |
0.374 |
|
| 2012 |
Reardon DA, Conrad CA, Cloughesy T, Prados MD, Friedman HS, Aldape KD, Mischel P, Xia J, DiLea C, Huang J, Mietlowski W, Dugan M, Chen W, Yung WK. Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients. Cancer Chemotherapy and Pharmacology. 69: 1507-18. PMID 22392572 DOI: 10.1007/S00280-012-1854-6 |
0.372 |
|
| 2012 |
Walter F, Cloughesy T, Walter MA, Lai A, Nghiemphu P, Wagle N, Fueger B, Satyamurthy N, Phelps ME, Czernin J. Impact of 3,4-dihydroxy-6-18F-fluoro-L-phenylalanine PET/CT on managing patients with brain tumors: the referring physician's perspective. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 53: 393-8. PMID 22323780 DOI: 10.2967/Jnumed.111.095711 |
0.35 |
|
| 2012 |
Reardon DA, Cloughesy T, Rich J, Alfred Yung WK, Yung L, DiLea C, Huang J, Dugan M, Mietlowski W, Maes A, Conrad C. Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma. Cancer Chemotherapy and Pharmacology. 69: 281-7. PMID 21984222 DOI: 10.1007/s00280-011-1754-1 |
0.332 |
|
| 2012 |
Gilbert MR, Kuhn J, Lamborn KR, Lieberman F, Wen PY, Mehta M, Cloughesy T, Lassman AB, Deangelis LM, Chang S, Prados M. Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery. Journal of Neuro-Oncology. 106: 147-53. PMID 21739168 DOI: 10.1007/S11060-011-0650-1 |
0.448 |
|
| 2012 |
Green R, Woyshner E, Quan J, Cloughesy T. Treatment of Unresectable Adult Pilocytic Astrocytoma with Bevacizumab with or without Temozolomide (P04.183) Neurology. 78: P04.183-P04.183. DOI: 10.1212/WNL.78.1_MEETINGABSTRACTS.P04.183 |
0.436 |
|
| 2012 |
Lassman AB, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Gregory Cairncross J, Urgoiti GBR, Wen PY, Ligon KL, Schiff D, et al. Response to Weltman and Fleury Malheiros, re Lassman et al. Neuro-Oncology. 14: 677-678. DOI: 10.1093/Neuonc/Nos136 |
0.33 |
|
| 2012 |
Kang J, Selch M, Cloughesy T, Kupelian P, Pajonk F, Wang J, Agazaryan N, Lee P. Radiation of Potential Local Cancer Stem Cell Niches Improves Survival of Patients With Glioblastoma Multiforme International Journal of Radiation Oncology*Biology*Physics. 84: S6-S7. DOI: 10.1016/J.Ijrobp.2012.07.023 |
0.304 |
|
| 2011 |
Chinot OL, Wick W, Saran F, Mason WP, Henriksson R, Nishikawa R, Zeaiter AH, Moore N, Das A, Cloughesy TF. AVAglio: A phase III trial of bevacizumab added to standard radiotherapy and temozolomide in patients with newly diagnosed glioblastoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: TPS136. PMID 28022889 DOI: 10.1200/jco.2011.29.15_suppl.tps136 |
0.321 |
|
| 2011 |
Cloughesy T. The impact of recent data on the optimization of standards of care in newly diagnosed glioblastoma. Seminars in Oncology. 38: S11-20. PMID 22078643 DOI: 10.1053/j.seminoncol.2011.09.007 |
0.392 |
|
| 2011 |
Lai A, Kharbanda S, Pope WB, Tran A, Solis OE, Peale F, Forrest WF, Pujara K, Carrillo JA, Pandita A, Ellingson BM, Bowers CW, Soriano RH, Schmidt NO, Mohan S, ... ... Cloughesy T, et al. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4482-90. PMID 22025148 DOI: 10.1200/Jco.2010.33.8715 |
0.346 |
|
| 2011 |
Wen PY, Schiff D, Cloughesy TF, Reardon DA, Batchelor TT, Chabner BA, Flaherty K, de Groot JF, Gilbert MR, Galanis E, Chang SM, Schwartz GK, Peereboom D, Mehta MP, Yung WK, et al. It is time to include patients with brain tumors in phase I trials in oncology. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3211-3. PMID 21768451 DOI: 10.1200/Jco.2011.36.6328 |
0.315 |
|
| 2011 |
de Groot JF, Piao Y, Tran H, Gilbert M, Wu HK, Liu J, Bekele BN, Cloughesy T, Mehta M, Robins HI, Lassman A, DeAngelis L, Camphausen K, Chen A, Yung WK, et al. Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 4872-81. PMID 21632852 DOI: 10.1158/1078-0432.Ccr-11-0271 |
0.348 |
|
| 2011 |
de Groot JF, Lamborn KR, Chang SM, Gilbert MR, Cloughesy TF, Aldape K, Yao J, Jackson EF, Lieberman F, Robins HI, Mehta MP, Lassman AB, Deangelis LM, Yung WK, Chen A, et al. Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2689-95. PMID 21606416 DOI: 10.1200/Jco.2010.34.1636 |
0.382 |
|
| 2011 |
Wefel JS, Cloughesy T, Zazzali JL, Zheng M, Prados M, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Das A, et al. Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro-Oncology. 13: 660-8. PMID 21558074 DOI: 10.1093/Neuonc/Nor024 |
0.41 |
|
| 2011 |
Chinot OL, de La Motte Rouge T, Moore N, Zeaiter A, Das A, Phillips H, Modrusan Z, Cloughesy T. AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Advances in Therapy. 28: 334-40. PMID 21432029 DOI: 10.1007/s12325-011-0007-3 |
0.402 |
|
| 2011 |
Pope WB, Lai A, Mehta R, Kim HJ, Qiao J, Young JR, Xue X, Goldin J, Brown MS, Nghiemphu PL, Tran A, Cloughesy TF. Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma. Ajnr. American Journal of Neuroradiology. 32: 882-9. PMID 21330401 DOI: 10.3174/Ajnr.A2385 |
0.309 |
|
| 2011 |
Wen PY, Schiff D, Cloughesy TF, Raizer JJ, Laterra J, Smitt M, Wolf M, Oliner KS, Anderson A, Zhu M, Loh E, Reardon DA. A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro-Oncology. 13: 437-46. PMID 21297127 DOI: 10.1093/neuonc/noq198 |
0.316 |
|
| 2011 |
Pope WB, Xia Q, Paton VE, Das A, Hambleton J, Kim HJ, Huo J, Brown MS, Goldin J, Cloughesy T. Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab. Neurology. 76: 432-7. PMID 21282590 DOI: 10.1212/WNL.0b013e31820a0a8a |
0.431 |
|
| 2011 |
Lai A, Tran A, Nghiemphu PL, Pope WB, Solis OE, Selch M, Filka E, Yong WH, Mischel PS, Liau LM, Phuphanich S, Black K, Peak S, Green RM, Spier CE, ... ... Cloughesy T, et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 142-8. PMID 21135282 DOI: 10.1200/Jco.2010.30.2729 |
0.445 |
|
| 2011 |
Prados M, Cloughesy T, Samant M, Fang L, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Das A, Friedman HS. Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Neuro-Oncology. 13: 143-51. PMID 21084434 DOI: 10.1093/Neuonc/Noq151 |
0.415 |
|
| 2011 |
Solis OE, Mehta RI, Lai A, Mehta RI, Farchoukh LO, Green RM, Cheng JC, Natarajan S, Vinters HV, Cloughesy T, Yong WH. Rosette-forming glioneuronal tumor: a pineal region case with IDH1 and IDH2 mutation analyses and literature review of 43 cases. Journal of Neuro-Oncology. 102: 477-84. PMID 20872044 DOI: 10.1007/S11060-010-0335-1 |
0.324 |
|
| 2011 |
Youssef M, Reinitz F, Cloughesy T, Mischel P, Guo D. Abstract C169: Inhibition of SREBPs by fatostatin reduces glioblastoma cell proliferation and viability. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-C169 |
0.307 |
|
| 2010 |
Wagle N, Nghiemphu L, Lai A, Pope W, Mischel PS, Cloughesy T. Update and developments in the treatment of glioblastoma multiforme - focus on bevacizumab. Pharmacogenomics and Personalized Medicine. 3: 79-85. PMID 23226044 DOI: 10.2147/Pgpm.S7940 |
0.389 |
|
| 2010 |
Vredenburgh JJ, Cloughesy T, Samant M, Prados M, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Das A, Friedman HS. Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. The Oncologist. 15: 1329-34. PMID 21147867 DOI: 10.1634/Theoncologist.2010-0105 |
0.419 |
|
| 2010 |
Fueger BJ, Czernin J, Cloughesy T, Silverman DH, Geist CL, Walter MA, Schiepers C, Nghiemphu P, Lai A, Phelps ME, Chen W. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 51: 1532-8. PMID 20847166 DOI: 10.2967/Jnumed.110.078592 |
0.372 |
|
| 2010 |
Yung WK, Vredenburgh JJ, Cloughesy TF, Nghiemphu P, Klencke B, Gilbert MR, Reardon DA, Prados MD. Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study. Neuro-Oncology. 12: 1061-70. PMID 20615922 DOI: 10.1093/Neuonc/Noq072 |
0.302 |
|
| 2010 |
Rockne R, Rockhill JK, Mrugala M, Spence AM, Kalet I, Hendrickson K, Lai A, Cloughesy T, Alvord EC, Swanson KR. Predicting the efficacy of radiotherapy in individual glioblastoma patients in vivo: a mathematical modeling approach. Physics in Medicine and Biology. 55: 3271-85. PMID 20484781 DOI: 10.1088/0031-9155/55/12/001 |
0.422 |
|
| 2010 |
Schiepers C, Dahlbom M, Chen W, Cloughesy T, Czernin J, Phelps ME, Huang SC. Kinetics of 3'-deoxy-3'-18F-fluorothymidine during treatment monitoring of recurrent high-grade glioma. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 51: 720-7. PMID 20395318 DOI: 10.2967/Jnumed.109.068361 |
0.311 |
|
| 2010 |
Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Aldape KA, Wen PY, Fine HA, Mehta M, Deangelis LM, Lieberman F, Cloughesy TF, et al. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro-Oncology. 12: 95-103. PMID 20150372 DOI: 10.1093/Neuonc/Nop015 |
0.306 |
|
| 2010 |
Lee Y, Liu J, Patel S, Cloughesy T, Lai A, Farooqi H, Seligson D, Dong J, Liau L, Becker D, Mischel P, Shams S, Nelson S. Genomic landscape of meningiomas. Brain Pathology (Zurich, Switzerland). 20: 751-62. PMID 20015288 DOI: 10.1111/J.1750-3639.2009.00356.X |
0.35 |
|
| 2010 |
Norden AD, Raizer JJ, Abrey LE, Lamborn KR, Lassman AB, Chang SM, Yung WK, Gilbert MR, Fine HA, Mehta M, Deangelis LM, Cloughesy TF, Robins HI, Aldape K, Dancey J, et al. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. Journal of Neuro-Oncology. 96: 211-7. PMID 19562255 DOI: 10.1007/S11060-009-9948-7 |
0.358 |
|
| 2009 |
Green RM, Cloughesy T, Stupp R, DeAngelis LM, Woyshner EA, Ney DE, Lassman AB. Bevacizumab for recurrent ependymoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2060. PMID 27964675 DOI: 10.1200/jco.2009.27.15_suppl.2060 |
0.311 |
|
| 2009 |
Lai A, Nghiemphu P, Green R, Spier L, Peak S, Phuphanich S, Fehrenbacher L, Kolevska T, Polikoff J, Cloughesy T. Phase II trial of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2000. PMID 27964565 DOI: 10.1200/jco.2009.27.15_suppl.2000 |
0.358 |
|
| 2009 |
Wang CH, Rockhill JK, Mrugala M, Peacock DL, Lai A, Jusenius K, Wardlaw JM, Cloughesy T, Spence AM, Rockne R, Alvord EC, Swanson KR. Prognostic significance of growth kinetics in newly diagnosed glioblastomas revealed by combining serial imaging with a novel biomathematical model. Cancer Research. 69: 9133-40. PMID 19934335 DOI: 10.1158/0008-5472.CAN-08-3863 |
0.424 |
|
| 2009 |
Green RM, Cloughesy TF, Stupp R, DeAngelis LM, Woyshner EA, Ney DE, Lassman AB. Bevacizumab for recurrent ependymoma. Neurology. 73: 1677-80. PMID 19917990 DOI: 10.1212/WNL.0b013e3181c1df34 |
0.415 |
|
| 2009 |
Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 4733-40. PMID 19720927 DOI: 10.1200/Jco.2008.19.8721 |
0.421 |
|
| 2009 |
Pope WB, Kim HJ, Huo J, Alger J, Brown MS, Gjertson D, Sai V, Young JR, Tekchandani L, Cloughesy T, Mischel PS, Lai A, Nghiemphu P, Rahmanuddin S, Goldin J. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology. 252: 182-9. PMID 19561256 DOI: 10.1148/Radiol.2521081534 |
0.363 |
|
| 2009 |
Wen PY, Yung WK, Lamborn KR, Norden AD, Cloughesy TF, Abrey LE, Fine HA, Chang SM, Robins HI, Fink K, Deangelis LM, Mehta M, Di Tomaso E, Drappatz J, Kesari S, et al. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro-Oncology. 11: 853-60. PMID 19293394 DOI: 10.1215/15228517-2009-010 |
0.322 |
|
| 2009 |
Butowski N, Lamborn KR, Lee BL, Prados MD, Cloughesy T, DeAngelis LM, Abrey L, Fink K, Lieberman F, Mehta M, Ian Robins H, Junck L, Salazar AM, Chang SM. A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas. Journal of Neuro-Oncology. 91: 183-9. PMID 18850068 DOI: 10.1007/s11060-008-9705-3 |
0.451 |
|
| 2009 |
Butowski N, Chang SM, Junck L, DeAngelis LM, Abrey L, Fink K, Cloughesy T, Lamborn KR, Salazar AM, Prados MD. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). Journal of Neuro-Oncology. 91: 175-82. PMID 18797818 DOI: 10.1007/s11060-008-9693-3 |
0.439 |
|
| 2009 |
Ledezma CJ, Chen W, Sai V, Freitas B, Cloughesy T, Czernin J, Pope W. 18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: initial experience. European Journal of Radiology. 71: 242-8. PMID 18511228 DOI: 10.1016/J.Ejrad.2008.04.018 |
0.323 |
|
| 2009 |
Wen PY, Omuro AM, Batchelor TT, Lai A, Mellinghoff IK, Nghiemphu L, Norden A, Gendreau SB, Laird AD, Nguyen L, Cloughesy T. Abstract B265: A Phase 1 safety and pharmacokinetic study of XL765 (SAR245409), a novel PI3K/TORC1/TORC2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with malignant glioma Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-B265 |
0.338 |
|
| 2008 |
Reardon DA, Fink KL, Mikkelsen T, Cloughesy TF, O'Neill A, Plotkin S, Glantz M, Ravin P, Raizer JJ, Rich KM, Schiff D, Shapiro WR, Burdette-Radoux S, Dropcho EJ, Wittemer SM, et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 5610-7. PMID 18981465 DOI: 10.1200/JCO.2008.16.7510 |
0.318 |
|
| 2008 |
Ananthnarayan S, Bahng J, Roring J, Nghiemphu P, Lai A, Cloughesy T, Pope WB. Time course of imaging changes of GBM during extended bevacizumab treatment. Journal of Neuro-Oncology. 88: 339-47. PMID 18389177 DOI: 10.1007/s11060-008-9573-x |
0.408 |
|
| 2008 |
Lamborn KR, Yung WK, Chang SM, Wen PY, Cloughesy TF, DeAngelis LM, Robins HI, Lieberman FS, Fine HA, Fink KL, Junck L, Abrey L, Gilbert MR, Mehta M, Kuhn JG, et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro-Oncology. 10: 162-70. PMID 18356283 DOI: 10.1215/15228517-2007-062 |
0.353 |
|
| 2008 |
Lai A, Filka E, McGibbon B, Nghiemphu PL, Graham C, Yong WH, Mischel P, Liau LM, Bergsneider M, Pope W, Selch M, Cloughesy T. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. International Journal of Radiation Oncology, Biology, Physics. 71: 1372-80. PMID 18355978 DOI: 10.1016/J.Ijrobp.2007.11.068 |
0.406 |
|
| 2008 |
Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, Liau L, Martin N, Becker D, Bergsneider M, Lai A, et al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. Plos Medicine. 5: e8. PMID 18215105 DOI: 10.1371/Journal.Pmed.0050008 |
0.327 |
|
| 2008 |
Prados MD, Yung WK, Wen PY, Junck L, Cloughesy T, Fink K, Chang S, Robins HI, Dancey J, Kuhn J. Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study. Cancer Chemotherapy and Pharmacology. 61: 1059-67. PMID 17694310 DOI: 10.1007/s00280-007-0556-y |
0.353 |
|
| 2007 |
Loghin ME, Prados MD, Wen P, Junck L, Lieberman F, Fine H, Fink KL, Metha M, Kuhn J, Lamborn K, Chang SM, Cloughesy T, DeAngelis LM, Robins IH, Aldape KD, et al. Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 7133-8. PMID 18056194 DOI: 10.1158/1078-0432.Ccr-07-0874 |
0.357 |
|
| 2007 |
Chen W, Delaloye S, Silverman DH, Geist C, Czernin J, Sayre J, Satyamurthy N, Pope W, Lai A, Phelps ME, Cloughesy T. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 4714-21. PMID 17947718 DOI: 10.1200/Jco.2006.10.5825 |
0.392 |
|
| 2007 |
Schiepers C, Chen W, Cloughesy T, Dahlbom M, Huang SC. 18F-FDOPA kinetics in brain tumors. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 48: 1651-61. PMID 17873130 DOI: 10.2967/Jnumed.106.039321 |
0.352 |
|
| 2007 |
Schiepers C, Chen W, Dahlbom M, Cloughesy T, Hoh CK, Huang SC. 18F-fluorothymidine kinetics of malignant brain tumors. European Journal of Nuclear Medicine and Molecular Imaging. 34: 1003-11. PMID 17295039 DOI: 10.1007/s00259-006-0354-5 |
0.353 |
|
| 2007 |
Groves MD, Puduvalli VK, Chang SM, Conrad CA, Gilbert MR, Tremont-Lukats IW, Liu TJ, Peterson P, Schiff D, Cloughesy TF, Wen PY, Greenberg H, Abrey LE, DeAngelis LM, Hess KR, et al. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. Journal of Neuro-Oncology. 81: 271-7. PMID 17031561 DOI: 10.1007/S11060-006-9225-Y |
0.327 |
|
| 2006 |
Tso CL, Shintaku P, Chen J, Liu Q, Liu J, Chen Z, Yoshimoto K, Mischel PS, Cloughesy TF, Liau LM, Nelson SF. Primary glioblastomas express mesenchymal stem-like properties. Molecular Cancer Research : McR. 4: 607-19. PMID 16966431 DOI: 10.1158/1541-7786.MCR-06-0005 |
0.434 |
|
| 2006 |
Mischel PS, Cloughesy T. Using molecular information to guide brain tumor therapy. Nature Clinical Practice. Neurology. 2: 232-3. PMID 16932555 DOI: 10.1038/ncpneuro0145 |
0.332 |
|
| 2006 |
Wen PY, Yung WK, Lamborn KR, Dahia PL, Wang Y, Peng B, Abrey LE, Raizer J, Cloughesy TF, Fink K, Gilbert M, Chang S, Junck L, Schiff D, Lieberman F, et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4899-907. PMID 16914578 DOI: 10.1158/1078-0432.Ccr-06-0773 |
0.311 |
|
| 2006 |
Cloughesy TF, Wen PY, Robins HI, Chang SM, Groves MD, Fink KL, Junck L, Schiff D, Abrey L, Gilbert MR, Lieberman F, Kuhn J, DeAngelis LM, Mehta M, Raizer JJ, et al. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 3651-6. PMID 16877733 DOI: 10.1200/Jco.2006.06.2323 |
0.313 |
|
| 2006 |
Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology. 66: 1258-60. PMID 16636248 DOI: 10.1212/01.Wnl.0000250628.10420.D8 |
0.334 |
|
| 2006 |
Prados MD, Lamborn K, Yung WK, Jaeckle K, Robins HI, Mehta M, Fine HA, Wen PY, Cloughesy T, Chang S, Nicholas MK, Schiff D, Greenberg H, Junck L, Fink K, et al. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro-Oncology. 8: 189-93. PMID 16533878 DOI: 10.1215/15228517-2005-010 |
0.354 |
|
| 2006 |
Chang SM, Lamborn K, Wen P, Deangelis L, Fink K, Lieberman F, Yung A, Robins I, Cloughesy T, Junck L, Prados M. Phase II study of POLY-ICLC in recurrent anaplastic glioma–A North American Brain Tumor Consortium study Journal of Clinical Oncology. 24: 1550-1550. DOI: 10.1200/JCO.2006.24.18_SUPPL.1550 |
0.337 |
|
| 2005 |
Chang SM, Wen P, Cloughesy T, Greenberg H, Schiff D, Conrad C, Fink K, Robins HI, De Angelis L, Raizer J, Hess K, Aldape K, Lamborn KR, Kuhn J, Dancey J, et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Investigational New Drugs. 23: 357-61. PMID 16012795 DOI: 10.1007/S10637-005-1444-0 |
0.43 |
|
| 2004 |
Puduvalli VK, Yung WK, Hess KR, Kuhn JG, Groves MD, Levin VA, Zwiebel J, Chang SM, Cloughesy TF, Junck L, Wen P, Lieberman F, Conrad CA, Gilbert MR, Meyers CA, et al. Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 4282-9. PMID 15514370 DOI: 10.1200/Jco.2004.09.096 |
0.311 |
|
| 2004 |
Freije WA, Castro-Vargas FE, Fang Z, Horvath S, Cloughesy T, Liau LM, Mischel PS, Nelson SF. Gene expression profiling of gliomas strongly predicts survival. Cancer Research. 64: 6503-10. PMID 15374961 DOI: 10.1158/0008-5472.CAN-04-0452 |
0.34 |
|
| 2004 |
Chang SM, Kuhn J, Wen P, Greenberg H, Schiff D, Conrad C, Fink K, Robins HI, Cloughesy T, De Angelis L, Razier J, Hess K, Dancey J, Prados MD. Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. Investigational New Drugs. 22: 427-35. PMID 15292713 DOI: 10.1023/B:Drug.0000036685.72140.03 |
0.35 |
|
| 2004 |
Parker RJ, Fruehauf JP, Mehta R, Filka E, Cloughesy T. A prospective blinded study of the predictive value of an extreme drug resistance assay in patients receiving CPT-11 for recurrent glioma. Journal of Neuro-Oncology. 66: 365-75. PMID 15015670 DOI: 10.1023/B:Neon.0000014549.77646.F6 |
0.442 |
|
| 2003 |
Jaeckle KA, Hess KR, Yung WK, Greenberg H, Fine H, Schiff D, Pollack IF, Kuhn J, Fink K, Mehta M, Cloughesy T, Nicholas MK, Chang S, Prados M. Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 2305-11. PMID 12805331 DOI: 10.1200/JCO.2003.12.097 |
0.393 |
|
| 2003 |
Cloughesy TF, Filka E, Kuhn J, Nelson G, Kabbinavar F, Friedman H, Miller LL, Elfring GL. Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Cancer. 97: 2381-6. PMID 12712460 DOI: 10.1002/Cncr.11306 |
0.307 |
|
| 2002 |
Wellisch DK, Kaleita TA, Freeman D, Cloughesy T, Goldman J. Predicting major depression in brain tumor patients. Psycho-Oncology. 11: 230-8. PMID 12112483 DOI: 10.1002/pon.562 |
0.358 |
|
| 2002 |
Cloughesy TF, Filka E, Nelson G, Kabbinavar F, Friedman H, Miller LL, Elfring GL. Irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. American Journal of Clinical Oncology. 25: 204-8. PMID 11943904 DOI: 10.1097/00000421-200204000-00022 |
0.311 |
|
| 2002 |
Robins HI, Chang SM, Prados MD, Yung WK, Hess K, Schiff D, Greenberg H, Fink K, Nicolas K, Kuhn JG, Cloughesy T, Junck L, Mehta M. A phase II trial of thymidine and carboplatin for recurrent malignant glioma: a North American Brain Tumor Consortium Study. Neuro-Oncology. 4: 109-14. PMID 11916502 DOI: 10.1215/S1522851701000515 |
0.442 |
|
| 2001 |
Doolittle ND, Anderson CP, Bleyer WA, Cairncross JG, Cloughesy T, Eck SL, Guastadisegni P, Hall WA, Muldoon LL, Patel SJ, Peereboom D, Siegal T, Neuwelt EA. Importance of dose intensity in neuro-oncology clinical trials: summary report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium. Neuro-Oncology. 3: 46-54. PMID 11305417 DOI: 10.1093/Neuonc/3.1.46 |
0.38 |
|
| 2000 |
Chow KL, Gobin YP, Cloughesy T, Sayre JW, Villablanca JP, Viñuela F. Prognostic factors in recurrent glioblastoma multiforme and anaplastic astrocytoma treated with selective intra-arterial chemotherapy. Ajnr. American Journal of Neuroradiology. 21: 471-8. PMID 10730637 |
0.324 |
|
| 2000 |
Haney S, Thompson P, Cloughesy T, Alger J, Toga A. Mapping tumor growth rates in patients with malignant gliomas: A test of two algorithms Neuroimage. 11: S905. DOI: 10.1016/S1053-8119(00)91833-0 |
0.325 |
|
| 1999 |
Cloughesy TF, Black KL, Gobin YP, Farahani K, Nelson G, Villablanca P, Kabbinavar F, Viñeula F, Wortel CH. Intra-arterial Cereport (RMP-7) and carboplatin: a dose escalation study for recurrent malignant gliomas. Neurosurgery. 44: 270-8; discussion 27. PMID 9932880 |
0.329 |
|
| 1997 |
Black KL, Cloughesy T, Huang SC, Gobin YP, Zhou Y, Grous J, Nelson G, Farahani K, Hoh CK, Phelps M. Intracarotid infusion of RMP-7, a bradykinin analog, and transport of gallium-68 ethylenediamine tetraacetic acid into human gliomas. Journal of Neurosurgery. 86: 603-9. PMID 9120622 DOI: 10.3171/Jns.1997.86.4.0603 |
0.356 |
|
| 1993 |
Cloughesy TF, Nuwer MR, Hoch D, Vinuela F, Duckwiler G, Martin N. Monitoring carotid test occlusions with continuous EEG and clinical examination. Journal of Clinical Neurophysiology : Official Publication of the American Electroencephalographic Society. 10: 363-9. PMID 8408601 |
0.614 |
|
| 1992 |
Nuwer MR, Banoczi WR, Cloughesy TF, Hoch DB, Peacock W, Levesque MF, Black KL, Martin NA, Becker DP. Topographic mapping of somatosensory evoked potentials helps identify motor cortex more quickly in the operating room. Brain Topography. 5: 53-8. PMID 1463660 DOI: 10.1007/BF01129970 |
0.576 |
|
| Show low-probability matches. |